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This review categorizes functionally validated actions of defined scorpion toxin (SCTX) neuropeptides
across ion channel subclasses, highlighting key trends in this rapidly evolving field. Scorpion enven-
omation is a common event in many tropical and subtropical countries, with neuropharmacological
actions, particularly autonomic nervous system modulation, causing significant mortality. The primary
active agents within scorpion venoms are a diverse group of small neuropeptides that elicit specific
potent actions across a wide range of ion channel classes. The identification and functional characteri-
sation of these SCTX peptides has tremendous potential for development of novel pharmaceuticals that
advance knowledge of ion channels and establish lead compounds for treatment of excitable tissue
disorders. This review delineates the unique specificities of 320 individual SCTX peptides that collectively
act on 41 ion channel subclasses. Thus the SCTX research field has significant translational implications
for pathophysiology spanning neurotransmission, neurohumoral signalling, sensori-motor systems and
excitation-contraction coupling.
This article is part of the Special Issue entitled ‘Venom-derived Peptides as Pharmacological Tools.’
© 2016 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Scorpion envenomation is a relatively common event in many
subtropical and tropical countries with about 1 million stings
annually, resulting in approximately 2600 fatalities, largely in
children (Chippaux and Goyffon, 2008). Stings from the Moroccan
black scorpion Androctonus mauretanicus mauretanicus for
example, have an 8% mortality rate in children under 10 years old
(Martin-Eauclaire and Bougis, 2012). With envenomation, pain and
swelling at the site is often followed by paraesthesia and hyper-
algesia lasting hours, with possible numbness and tingling lasting
days. Systemic effects, such as nausea, vomiting, malaise, tachy-
cardia, and seizures, are seen in about 10% of cases and are thought
to be the result of autonomic nervous system dysregulation
(Nicholson et al., 2006). Scorpion venom typically contains a
complex mixture of small peptides, proteins (enzymes, phospho-
lipases, and proteases), amino acids, biogenic amines, lipids, car-
bohydrates, and inorganic salts (Ortiz et al., 2015). The physiological
effects of scorpion envenomation, such as modulation of central
and peripheral nervous system excitability, altered smooth and
skeletal muscle activity, and membrane destabilisation, are pri-
marily mediated through the action of small neuropeptides on
various ion channels in excitable membranes, a process thought to
have developed in response to extended positive selection pressure
via predator-prey interactions (Menez et al., 1992;Goudet et al.,
2002;Tytgat et al., 1999). These peptides can be characterised
generically (disulfide bridge-containing peptides and non-disulfide
bridge-containing peptides) (Zeng et al., 2005), or by the size of the
peptide chain (short chain peptides, usually potassium channel
blockers, or long-chain peptides, usually sodium channel modula-
tors) (Quintero-Hernandez et al., 2015;Santibanez-Lopez and
Possani, 2015).
This review comprehensively synthesises the available func-
tional data regarding the actions of individually identified SCTX
peptides on specific ion channel targets across the main classes of
ion channel superfamilies, including voltage-gated sodium chan-
nels (Nav), voltage-gated potassium channels (Kv), calcium-
activated potassium channels (KCa), as well as chloride channels
and Ca2þ channels. The breadth of SCTX actions on ion channels are
summarized schematically in Fig. 1.Fig. 1. Summary of major classes of ion channels targeted by scorpion toxin neuro-
peptides. Details of channel subclasses and specific SCTX peptide actions are provided
in Table 1e5.1.1. Overview of SCTX actions on voltage-gated sodium channels
Nav channels are present in the plasma membrane of most
excitable cells and are responsible for the initiation and propaga-
tion of action potentials (Catterall et al., 2005a). There is one family
of mammalian Nav channels with nine functional subtypes
(Nav1.1e1.9), encoded by multiple genes within species. In contrast
invertebrates possess one functional Nav channel, with a number of
orthologs, with functional diversity generated thorugh alternative
splicing and RNA editing (Zakon, 2012;Dong et al., 2014). Mamal-
lian Nav channels are comprised of 1 pore-forming a-subunit
associated with 1e2 b subunits (b1-b4 or TipE subunits in insects)
(Dong et al., 2014). The a-subunits consist of four homologous
domains (I-IV) each with 6 transmembrane segments (S1eS6) and
a pore-forming loop, as well as a recently identified Naþ-selectivity
filter (Payandeh et al., 2011). The b accessory subunits have a largeextracellular N-terminal domain, a single transmembrane segment,
and a shorter cytoplasmic domain, and alter the kinetics and
voltage-dependence of channel gating, as well as channel locali-
zation and interaction with surrounding structures (Catterall et al.,
2005a;Gordon et al., 2007;Alexander et al., 2015a). Sodium channel
SCTX ‘long-chain’ peptides are typically 6.5e8.5 kDa polypeptides
containing 58e76 amino acid residues, forming a common struc-
tural core secured by four disulfide bridges (Rodriguez de la Vega
and Possani, 2005;Quintero-Hernandez et al., 2013). They have
been functionally divided into alpha or beta toxins according to
their primary actions on these channels. Scorpion a-toxins target
the Nav receptor site 3 slowing or inhibiting channel inactivation,
thereby enhancing persistent activation (Catterall, 1992;du Plessis
et al., 2008;Possani et al., 1999). These toxins can be further clas-
sified as the common “classical” mammalian-selective toxins,
insect-specific alpha toxins, or alpha-like toxins, acting on both
mammals and insects (Quintero-Hernandez et al., 2013). In
contrast, b-toxins bind to receptor site 4 and hyperpolarise the Nav
channel activation threshold to more negative voltages. These are
divided into 4 subtypes; anti-mammalian-selective, mammalian
and insect, insect-selective excitatory, or insect-select depressant
toxins (Quintero-Hernandez et al., 2013;Pedraza Escalona and ,
2013;de la Vega, 2007;Ortiz and Possani, 2015).
1.2. Overview of SCTX actions on potassium channels
Potassium channels are the largest and most diverse group of
ion channels, represented by 70 known loci in the mammalian
genome (Gutman et al., 2005). They typically consist of a primary
pore-forming a-subunit, and are often associated with auxillary
regulatory subunits (Alexander et al., 2015a). These channels can be
divided into 2 transmembrane domain (2TM), 4TM, and 6TM
groups (Alexander et al., 2015a), and contain families such as Kv,
KCa, inward rectifier potassium channels (Kir), and two-pore po-
tassium channels (K2p) (Gutman et al., 2005;Dutertre and Lewis,
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Ether-a-go-go-Related Gene (ERG) channels, as part of the ether-
a-go-go gene (EAG) group (Jimenez-Vargas et al., 2012a). Potassium
channels typically have inhibitory effects and act to reduce cellular
excitability, such as promoting cell repolarisation after action po-
tential firing (Martin-Eauclaire and Bougis, 2012). Kþ channel
toxins (KTx), usually short-chain peptides, can broadly influence
physiological function, including modulation of neuronal activity,
neurotransmitter release and hormonal secretion, lymphocyte
activation, muscle contractility, and the cardiac cycle (du Plessis
et al., 2008). They have been systematically organised into a, b, g,
and k-KTx families, classified based on primary amino acid se-
quences and the cysteine pairing (Quintero-Hernandez et al., 2013).
Of these the aeKTx family is the largest, consisting of 30 sub-
families, and can either block ion conduction in Kv1, KCa2, and KCa3
channels via intrusion of a conserved essential dyad, a paired lysine
and aromatic residue, into the channel selectivity filter, or by
binding to the negatively charged extracellular loop of the KCa2
channel (Tytgat et al., 1999;Quintero-Hernandez et al.,
2013;Dutertre and Lewis, 2010;Nirthanan et al., 2005;Rodriguez
de la Vega and. Possani, 2004). Peptides of the b-family can be
further divided into three subgroups, with the third group con-
taining Scorpine-like peptides with prominent antimicrobial ef-
fects. Ergtoxins of the g-family block ERG-Kþ channels, while k-
peptides are known as hefutoxins and lack the conserved Csab
motif found across the other families (Santibanez-Lopez and
Possani, 2015;Quintero-Hernandez et al., 2013).
1.3. Overview of SCTX actions on calcium channels
Calcium channels are widely distributed in many tissue types
and have been characterised in cardiac myocytes, smooth and
skeletal muscle, neuronal tissue, and endocrine cells (Catterall
et al., 2005b). Calcium channels can be divided into voltage-
gated, voltage-independent, and ligand-gated channels (Quintero-
Hernandez et al., 2013;du Plessis et al., 2008). Voltage-gated cal-
cium channels form hetero-oligomeric complexes within the
plasma membranes of all excitable cells, and underlie a number of
pathological processes including epilepsy, chronic pain, heart fail-
ure and hypertension (Lee et al., 2011). These channels are
comprised of a pore-forming transmembrane a-subunit, of which
there are 10 known mammalian varients (Alexander et al., 2015a).
SCTX peptides predominantly bind to the a-subunit (Alexander
et al., 2015a). Voltage-gated calcium channels are grouped into
three families: High-voltage activated dihydropyridine-sensitive
(L-type, Cav1. x) channels; High-voltage activated
dihydropyridine-insensitive (Cav2. x) channels; Low-voltage-
activated (T-type, Cav3. x) channels (Alexander et al., 2015a). For
at least the high-voltage activated calcium channel family, it is likey
that the a-subunit coassembles with b, a2-d subunits that modulate
channel properties, with g ancillary subunits only proven to asso-
ciate with a1s skeletal muscle Cav1.1 channel (Alexander et al.,
2015a;Norton and McDonough, 2008). Kurtoxin (Parabuthus
transvaalicus) is one of the few SCTX peptides identified to inhibit
voltage-gated calcium channels, initially demonstrating high af-
finity for low-voltage-activated calcium channels (Chuang et al.,
1998), and then also showing action on high-voltage calcium
channels (Sidach and Mintz, 2002), as well a range of Nav channels.
Ryanodine receptors (RyR1-3) are large channel macromolec-
ular complexes, associated with accessory proteins and secondary
messengers, that release calcium from intracellular stores located
in the endo/sarcoplasmic reticulum when activated by ligands
(including the plant alkaloid ryanodine), Ca2þ, or by allosteric
coupling to the L-type Ca2þ channel (Franzini-Armstrong and
Protasi, 1997;Bers, 2004;Alexander et al., 2015b). Ryanodinechannels vary in their tissue distribution with RyR1 predominantly
found in fast and slow-twitch skeletal muscle and in cerebellar
Purkinje cells (Takeshima et al., 1989), RyR2 is primarily in cardiac
muscle, as well as in brain and in visceral and arterial smooth
muscle (Nakai et al., 1990). RyR3 is found in the diaphragm,
epithelial cells, brain, and smoothmuscle (Hakamata et al., 1992;Fill
and Copello, 2002). SCTX peptides termed calcins can target these
channels, although characterisation has been limited until recently
(Quintero-Hernandez et al., 2013;Xiao et al., 2016). Calcins are able
to penetrate cell membranes with high efficiency, before rapidly
binding with high affinity to RyRs, increasing their activity by
inducing long-lasting sub-conductance states, and thereby leading
to increases in intracellular Ca2þ (Xiao et al., 2016;Tripathy et al.,
1998;Gurrola et al., 2010;Schwartz et al., 2009). Raised intracel-
lular Ca2þ serves as a second-messenger, increasing cellular excit-
ability, neurotransmitter release, intracellular metabolism, and
gene expression (du Plessis et al., 2008). Calcins are also able to
carry large membrane-impermable molecules across the mem-
brane with them, with obvious implications for intracellular drug
delivery (Boisseau et al., 2006).
1.4. Overview of SCTX actions on chloride channels
The chloride channel superfamily includes the voltage-sensitive
CIC sub-family, calcium-activated channels, high (maxi) conduc-
tance channels, the cystic fibrosis transmembrane conductance
regulator (CFTR), and volume-regulated channels (Alexander et al.,
2015b;Jentsch et al., 2002). The mammalian CIC family contains 9
members, divided into three subgroups, incorporating plasma
membrane channels and Cl/Hþ antiporters, and are thought to
contribure to plasma membrane transport, lysosomal acidification,
and the maintaince of cell membrane potential (Alexander et al.,
2015b;Jentsch et al., 2002;Thompson et al., 2009). CFTR is a 12
transmembrane, cAMP-regulated epithelial cell membrane chlo-
ride channel involved in normal fluid transport across epithelia
(Alexander et al., 2015b). Although the action of SCTX peptides on
chloride channels is poorly defined, GaTx1 and GaTx2 (Leiurus
quinquestriatus herbareus) have recently been identified to inhibit
the CFTR and CIC2 channels respectively (Thompson et al.,
2009;Fuller et al., 2007).
1.5. Scope of review
The characterization of SCTX peptide actions on ion channels
continues to grow at a rapid pace, aided by the development of
novel molecular technologies and experimental approaches. Pre-
vious reviews have focused on the structural, computational, and
molecular analysis of scorpion venom components and ion channel
interactions (Smith et al., 2014;Gurevitz et al., 2014), as well as
functional comparison of their actions on ion channels. Although
some reviews have outlined a broad overview of SCTX peptide
action (Ortiz et al., 2015;Quintero-Hernandez et al., 2013;du Plessis
et al., 2008), the majority have provided relatively detailed infor-
mation of SCTX action within particular ion channel subfamilies,
such as sodium channels Gordon et al., 2007;Pedraza Escalona and
Possani, 2013;Pucca et al., 2015a;Gilchrist and Bosmans,
2012;Gordon and Gurevitz, 2003), potassium channels Martin-
Eauclaire and Bougis, 2012;Jimenez-Vargas et al., 2012a;Bartok
et al., 2015;Yu et al., 2016;Bougis and Martin-Eauclaire, 2015;Yang
et al., 2015;Wang et al., 2014;Wanke and Restano-Cassulini, 2007),
and to a lesser extent, calcium Norton and McDonough,
2008;Ramos-Franco and Fill, 2016), and chloride channels
Dardevet et al., 2015). This review establishes a comprehensive
comparison of the broad range of functionally-validated SCTX
peptide actions across the breadth of ion channel families. We
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of known molecules, based on the characterization of their selec-
tivity within 41 functional channels. This review highlights the
desirability of expanding reproducible screening of these SCTX
peptides across the full breadth of known ion channels.
2. Methods
PubMed/Medline and the Scopus databases were searched to
identify studies that had specifically elicited the action of a defined
SCTX on particular ion channel subtypes. Publications focusing on
the use of whole venom and fractions were excluded as these
typically contain a multitude of individual peptides, confounding
any attempt to quantify molecular effect.
Data were extracted from the primary literature to identify the
scorpion peptide nomenclature, species of origin, ion channel
subtype (and its species origin), expression system, the effect
noted, and the necessary concentrations. This informationwas then
synthesised and organised according to the specific effects of
defined peptides on particular ion channel subtypes.
The data were arranged to highlight the action of unique and
well-defined SCTX peptides on the most specific ion channel sub-
classes known. To this end, the positive findings from the studies
have been highlighted in the body of the text and summarized
within tables based on ion channel classes. Negative findings were
not integrated into these tables.
3. Analysis of isolated SCTX neuropeptides on ion channel
targets
3.1. Scorpion venom peptide actions on voltage-gated sodium
channels
63 unique SCTX peptides with specific action on voltage-gated
sodium channels are described in Table 1. These peptides acted
by three main mechanisms: Direct inhibition of current flow;
hyperpolarisation of the channel activation threshold, or by
delaying or inhibiting channel inactivation. These actions occurred
over a wide range of SCTX peptide concentrations, from 100 pM
(Meng et al., 2015), to greater than 30 mM (Dai et al., 2012), sug-
gesting that there was significant variability in peptide affinity for
these channels. Table 1 also highlights the significant distinction in
the selectivity of SCTX peptides. 19 peptides appeared to be highly
selective, with action only characterised on one particular subtype
of ion channel in a multi-channel screen. In contrast, other SCTX
peptides, such as MeuNaTxa-5 (Mesobuthus eupeus), and OD1
(Odonthobuthus doriae), appeared to have much broader action,
each modulating 6 different channel subtypes. However, it is
important to note that many of the studies were restricted in the
breath of their target screening. Some identified peptides demon-
strated the ability to discriminate between mammalian and non-
mammalian channel subtypes. For example, AaHIT (Androctonus
australis Hector) (Bosmans et al., 2007) and BjaIT (Buthotus judai-
cus) (Arnon et al., 2005) were highly selective against insect
channel orthologues. In contrast Css VI (Centruroides suffusus suf-
fusus) affected rat Nav1.2 at 5 mM, but did not affect DMNaV1
(Bosmans et al., 2007). Such differences are likely to be due to
differences in ion channel amino acid sequence affecting the site of
toxin action.
MeuNaTxa-12 (Mesobuthus eupeus) was one of the most specific
inhibitors of the DMNaV1 channel with an EC50 of 20 nM, 45 fold
higher affinity than for rat Nav1.1 and significantly higher affinities
than for the rest of the Nav1 subfamily (Zhu et al., 2013). Cn8
(Centruroides noxius) had the greatest affinity for Nav1.1
(Kd ¼ 140 nM), although it was found to also have action on Nav1.2and Nav1.6 at similar concentrations (Schiavon et al., 2012). Amm
VIII (Androctonus mauretanicus mauretanicus) and AaH2 (Androc-
tonus australis Hector) are both potent Nav1.2 inhibitory peptides;
EC50 ¼ 29 nM and 2.6 nM respectively. However AmmVIII has
subsequently been shown to be significantly more selective for
Nav1.2 over Nav1.4 with a EC50 of 416 nM compared to 2.2 nM for
AaH2 (Alami et al., 2003). Tf2 (Tityus fasciolatus) was the only
Nav1.3 selective activator identified, with no action on Nav1.1e1.2,
or Nav1.4e1.8 channels expressed in Xenopus oocutes following
1 mM application (Camargos et al., 2015). Bmk AGP-SYPU1 (Buthus
martensii Karsch) had high affinity for Nav1.4 and Nav1.5, acting in
picomolar concentrations (Meng et al., 2015). However it has
similar preference for both channels, causing inhibition at 100 pM,
and has not been further characterised in other ion channel sub-
classes. The most selective inhibitor of Nav1.4 was the peptide Cell9
(Centruroides elegans). This toxin specifically targeted Nav1.4 when
applied at 700 nM, while leaving Nav1.2, Nav1.5 and Nav1.7 unaf-
fected (Vandendriessche et al., 2010).
Of the toxins showing a degree of preference to Nav1.5, BmK1
(Buthus martensii Karsch), Lqh III (Leiurus quinquestriatus hebraeus)
and Ts1 (Tityus serrulatus) are the best characterised. Nav1.6 was
selectively inhibited by peptide Cn2 (Centruroides noxius) with an
ED50 of 39.2 nM after screening on channels Nav1.1eNav1.7,
demonstrating unique selectivity. Nav1.7 was found to be potently
inhibited by peptide OD1 (Odonthobuthus doriae) with an EC50 of
4.5 nM, however it was not particularly selective, affecting Nav1.4
and Nav1.6 at similar concentrations (Maertens et al., 2006).
However a triple mutant of this peptide was engineered and found
to increase selectivity by up to 40 fold (Maertens et al., 2006),
indicating the great scope to tailor SCTX to specific molecular tar-
gets. Scorpion action on channels Nav1.8 and 1.9 is relatively poorly
defined. The sole peptide definitively found to affect Nav1.8 was
BMK I (Buthus martensii Karsch) with an EC50 of 302.95 nM (Ye
et al., 2015). However this peptide is not selective and affects
other Nav1 family channels at similar concentrations. AmmVIII and
AaH1 were found not to alter the Nav1.9 current in DRG neurons
(Abbas et al., 2013). Recent publications have suggested that Tityus
bahiensis scorpion venom (TbScV) (Moraes et al., 2011) and TsVII
(Tityus serrulatus) (Gilchrist and Bosmans, 2012) have potential
action on Nav1.8 and Nav1.9 channels, although this requires
further assessment and characterization.
3.2. Scorpion toxin peptide actions on voltage-gated potassium
channels
All peptide toxins acting on voltage-gated potassium channels
described in Tables 2 and 3 were inhibitory with the exception of
the excitatory peptide AaTXKb2e64 (Androctonus australis) (Zhu
et al., 2009c). There was marked variation in peptide selectivity
for ion channel subclasses. We found 43 SCTX peptides with
identified action restricted to a particular Kv subclass, however not
all of these have been subjected to comprehensive testing across
ion channel subfamilies. In contrast, 36 SCTX peptides were more
promiscuous, acting on 3 or more Kv subclasses. Some peptides
were selective between mammalian and non-mammalian chan-
nels. For example 9 SCTX peptides have been shown to be highly
selective at blocking the non-mammalian Shaker potassium
channels in invertebrates. Of these Agitoxin 1 (Leiurus quinques-
triatus hebraeus) is among the most potent SCTXs, with a Ki of 160
pM (Garcia et al., 1994).
Table 2 shows peptides with action on the Kv1 and Kv4 families.
Channel subclasses have only been included where a peptide has
been demonstrated to cause a functional effect. SCTX action on
Kv1.1e1.3 has been highly researched, with 74 peptides currently
identified as having blocking effects with wide variation in their
Table 1
Action of scorpion toxin peptides on voltage-gated sodium channels.
Peptide Species DmNav1 (Para) Nav1.1 Nav1.2 Nav1.3 Nav1.4 Nav1.5 Nav1.6 Nav1.7 Nav1.8
AaBTX-L1 Androctonus australis Hyperpolarisation
of activation
threshold,
Xenopus oocytes,
500 nM, (Martin-
Eauclaire et al.,
2005)
AaH I Androctonus australis
Hector
Inhibit
inactivation,
TSA21, 0.5 mM,
(M'Barek et al.,
2004)
AaH II Androctonus australis
Hector
Delayed
inactivation, Rat,
Xenopus oocytes,
EC50 ¼ 2.6 nM,
(Alami et al., 2003)
Inhibit
inactivation and
increased current,
Rat, Xenopus
oocytes, 50 nM,
(Maertens et al.,
2006)
Delayed
inactivation, Rat,
Xenopus oocytes,
EC50 ¼ 2.2 nM,
(Alami et al., 2003)
Inhibit
inactivation and
increased current,
Rat, Xenopus
oocytes, 50 nM,
(Maertens et al.,
2006); Impaired
fast inactivation,
Human, HEK293,
EC50 ¼ 6.8 nM,
(Abbas et al., 2013)
AaHIT Androctonus australis
Hector
Hyperpolarisation
of activation
threshold,
Xenopus oocytes,
500 nM, (Bosmans
et al., 2007)
AamH1 Androctonus amoreuxi Increase current
and slow
inactivation,
Xenopus oocytes,
0.1 mM, (Abbas
et al., 2008)
Increase current
and slow
inactivation, Rat,
Xenopus oocytes,
0.5 mM, (Abbas
et al., 2008)
AamH2 Androctonus amoreuxi Increase current
and slows
inactivation,
Xenopus oocytes,
0.1 mM, (Abbas
et al., 2009)
Increase current
and slows
inactivation, Rat,
Xenopus oocytes,
0.5 mM, (Abbas
et al., 2009)
Increase current
and slows
inactivation, Rat,
Xenopus oocytes,
0.5 mM, (Abbas
et al., 2009)
Amm VIII Androctonus
mauretanicus
mauretanicus
Delayed
inactivation, Rat,
Xenopus oocytes,
EC50 ¼ 29 nM,
(Alami et al., 2003)
Delayed
inactivation, Rat,
Xenopus oocytes,
EC50 ¼ 416 nM,
(Alami et al., 2003)
Impaired fast
inactivation,
Human, HEK293,
EC50 ¼ 1.76 mM,
(Abbas et al., 2013)
Bactridine 2 Tityus discrepans Hyperpolarisation
of activation and
reduction of peak
current (33%), Rat,
Xenopus oocytes,
100 nM, (Peigneur
et al., 2012)
Hyperpolarisation
of activation and
reduction of peak
current (63%), Rat,
Xenopus oocytes,
100 nM, (Peigneur
et al., 2012)
Hyperpolarisation of
activation, Rat, Xenopus
oocytes, 100 nM,
(Peigneur et al., 2012)
Bactridine 3 Tityus discrepans
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Hyperpolarisation
of activation and
reduction of peak
current (11%), Rat,
Xenopus oocytes,
100 nM, (Peigneur
et al., 2012)
Hyperpolarisation
of activation and
reduction of peak
current (64%), Rat,
Xenopus oocytes,
100 nM, (Peigneur
et al., 2012)
Hyperpolarisation of
activation, Rat, Xenopus
oocytes, 100 nM,
(Peigneur et al., 2012)
Bactridine 4 Tityus discrepans Hyperpolarisation
of activation and
reduction of peak
current (45%), Rat,
Xenopus oocytes,
100 nM, (Peigneur
et al., 2012)
Hyperpolarisation
of activation and
reduction of peak
current (21%), Rat,
Xenopus oocytes,
100 nM, (Peigneur
et al., 2012)
Hyperpolarisation of
activation, Rat, Xenopus
oocytes, 100 nM,
(Peigneur et al., 2012)
Bactridine 5 Tityus discrepans Reduction of peak
current (10%), Rat,
Xenopus oocytes,
100 nM, (Peigneur
et al., 2012)
Bactridine 6 Tityus discrepans Hyperpolarisation
of activation and
reduction of peak
current (34%), Rat,
Xenopus oocytes,
100 nM, (Peigneur
et al., 2012)
Slowed
inactivation, Rat,
Xenopus oocytes,
100 nM, (Peigneur
et al., 2012)
BjaIT Buthotus judaicus Complete
inhibition of
inactivation,
Xenopus oocytes,
100 nM, (Arnon
et al., 2005)
BmK 11(2) Buthus martensii Karsch Hyperpolarisation
of activation
threshold,
Increased current
(40%), slowed
inactivation, Rat,
HEK293, 100 nM,
(Kondratiev et al.,
2003)
Reduced current
(15%) and
slowed
inactivation,
Human, HEK293,
100 nM,
(Kondratiev
et al., 2003)
Bmk AGP-
SYPU1
Buthus martensii Karsch Increased current,
Human, CHO cells,
100 pM, (Meng
et al., 2015)
Increased
current, Human,
CHO, 100 pM,
(Meng et al.,
2015)
BmK AS Buthus martensii Karsch Hyperpolarisation
of activation
threshold and
depolarisation of
inactivation, Rat,
Xenopus oocytes,
500 nM, (Tan et al.,
2008); U-shaped
modulation of
activation by dose,
Rat, Xenopus
oocytes, nM, (Zhu
et al., 2009a)
Inhibits slow
inactivation and
facilitates steady-
state activation,
Rat, Xenopus
oocytes, 100 nmol/
L, (Liu et al., 2012)
(continued on next page)
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Table 1 (continued )
Peptide Species DmNav1 (Para) Nav1.1 Nav1.2 Nav1.3 Nav1.4 Nav1.5 Nav1.6 Nav1.7 Nav1.8
BmK I Buthus martensii Karsch Inhibit
inactivation and
increased current,
Rat, Xenopus
oocytes, 500 nM,
(Zhu et al., 2009b)
Inhibit
inactivation
increasing peak
current, Rat,
HEK293,
EC50 ¼ 99.4 nM,
(Feng et al.,
2008)
Inhibit fast inactivation
and increases current,
Mouse, Xenopus oocytes,
EC50 ¼ 214 nM, (He et al.,
2010)
Inhibit inactivation
and
hyperpolarisation
of activation
threshold, DRG
neurons,
EC50 ¼ 302.95 nM,
(Ye et al., 2015)
BmK IT2 Buthus martensii Karsch Hyperpolarised
activation
threshold and
inhibit current,
Xenopus oocytes,
EC50 ¼ 2.9 mM, (He
et al., 2011)
BmK M1 Buthus martensii Karsch Slow
inactivation and
hyperpolarise
steady state
inactivation,
Human, Xenopus
oocytes,
EC50 ¼ 195 nM,
(Goudet et al.,
2001)
Inhibit fast
inactivation and
increased current,
Rat - Xenopus
oocytes, 50 nM,
(Maertens et al.,
2006)
BmK aIV Buthus martensii Karsch Prolonged
inactivation and
increased current,
Rat, Xenopus
oocytes, 100 nM,
(Chai et al., 2006)
BmKITc Buthus martensii Karsch Inhibit slow
inactivation,
Xenopus oocytes,
3 mM, (Yuan et al.,
2010)
BmKITc2 Buthus martensii Karsch Inhibit slow
inactivation,
Xenopus oocytes,
3 mM, (Yuan et al.,
2010)
BmaTX14 Buthus martensii Karsch Inhibit fast
inactivation, Rat,
HEK293 cells,
EC50 ¼ >30 mM,
(Dai et al., 2012)
Inhibit fast
inactivation,
Mouse,
HEK293 cells,
EC50 ¼ 82.3 nM,
(Dai et al., 2012)
BmaTX47 Buthus martensii Karsch Inhibit fast
inactivation, Rat,
HEK293,
EC50 ¼ 7.26 mM, (Li
et al., 2014)
Inhibit fast
inactivation,
Mouse, HEK293,
10 mM, (Li et al.,
2014)
Inhibit fast
inactivation,
Human, HEK293,
EC50 ¼ 1 mM, (Li
et al., 2014)
CeII8 Centruroides elegans Hyperpolarisation
of activation
threshold and
inhibit current,
Rat, Xenopus
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oocytes, 300 nM,
(Vandendriessche
et al., 2010)
CeII9 Centruroides elegans Hyperpolarisation
of activation
threshold and
inhibit current,
Rat, Xenopus
oocytes, 700 nM,
(Vandendriessche
et al., 2010)
Cii1 Centruroides infamatus
infamatus
Inhibit current,
Rat, Xenopus
oocytes, 1.7 mM,
(Dehesa-Davila
et al., 1996)
Cll1 Centruroides limpidus
limpidus
Hyperpolarisation
of activation
threshold and
inhibit current,
HEK293, 560 nM,
(Schiavon et al.,
2012)
Hyperpolarisation
of activation
threshold and
inhibit current
HEK293, 560 nM,
(Schiavon et al.,
2012)
Hyperpolarisation of
activation threshold and
inhibit current, HEK293,
Kd ¼ 44.9 nM, (Schiavon
et al., 2012)
Cll2 Centruroides limpidus
limpidus
Hyperpolarisation
of activation
threshold and
inhibit current,
HEK293, 460 nM,
(Schiavon et al.,
2012)
Hyperpolarisation
of activation
threshold and
inhibit current,
HEK293, 460 nM,
(Schiavon et al.,
2012)
Inhibit current Rat,
Xenopus oocytes,
1.2 mM, (Dehesa-
Davila et al., 1996)
Hyperpolarisation of
activation threshold and
inhibit current, HEK293,
Kd ¼ 172 nM, (Schiavon
et al., 2012)
Cn2 Centruroides noxius Inhibition of
current, Rat,
Xenopus oocytes,
0.5 mM, (Dehesa-
Davila et al., 1996)
Hyperpolarisation of
activation threshold,
Human,
HEK293ED50 ¼ 39.2 nM,
(Schiavon et al., 2006)
Cn8 Centruroides noxius Hyperpolarisation
of activation
threshold and
inhibit current,
HEK293, 140 nM,
(Schiavon et al.,
2012)
Hyperpolarisation
of activation
threshold and
inhibit current,
HEK293, 140 nM,
(Schiavon et al.,
2012)
Hyperpolarisation of
activation threshold and
inhibit current, HEK293,
Kd ¼ 67.7 nM, (Schiavon
et al., 2012)
Css II Centruroides suffusus
suffusus
Hyperpolarisation
of activation
threshold and
inhibit current,
HEK293, 280 nM,
(Schiavon et al.,
2012)
Hyperpolarisation
of activation
threshold and
inhibit current,
HEK293, 280 nM,
(Schiavon et al.,
2012);
Hyperpolarisation
of activation
threshold, Rat,
Xenopus oocytes,
5 mM, (Bosmans
et al., 2007)
Hyperpolarisation of
activation threshold and
inhibit current, HEK293,
Kd ¼ 307 nM, (Schiavon
et al., 2012)
Css IV Centruroides suffusus
suffusus
Hyperpolarisation
of activation
threshold,
Xenopus oocytes,
Hyperpolarisation
of activation
threshold, Rat,
Xenopus oocytes,
(continued on next page)
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Table 1 (continued )
Peptide Species DmNav1 (Para) Nav1.1 Nav1.2 Nav1.3 Nav1.4 Nav1.5 Nav1.6 Nav1.7 Nav1.8
5 mM, (Bosmans
et al., 2007)
5 mM, (Bosmans
et al., 2007)
Css VI Centruroides suffusus
suffusus
Hyperpolarisation
of activation
threshold, Rat,
Xenopus oocytes,
5 mM, (Bosmans
et al., 2007)
CvIV4 Centruroides vittatus Inhibit fast
inactivation, Rat,
HEK293, 1 mM,
(Rowe et al., 2011)
Inhibit fast
inactivation, Rat,
HEK293, 1 mM,
(Rowe et al., 2011)
Inhibit fast
inactivation, Rat,
HEK293, 1 mM,
(Rowe et al., 2011)
Inhibit fast
inactivation,
Human, HEK293,
1 mM, (Rowe et al.,
2011)
Kbot55a-
Ktx31.1
Buthus occitanus
tunetanus
Inhibit current
(32%), Rat,
Xenopus oocytes,
1 mM, (ElFessi-
Magouri et al.,
2015)
Full Inhibit
current, Rat,
Xenopus oocytes,
1 mM, (ElFessi-
Magouri et al.,
2015)
Inhibition of
current (83%),
Human, Xenopus
oocytes, 1 mM,
(ElFessi-Magouri
et al., 2015)
Inhibit current (21%), Rat
e Xenopus oocytes, 1 mM,
(ElFessi-Magouri et al.,
2015)
Kurtoxin
Kurtoxin-
Like II
(Identical)
Parabuthus
transvaalicusParabuthus
granulatus
Slows activation
and inactivation,
Rat, Xenopus
oocytes,
500 nM, (Chuang
et al., 1998)
Delays
inactivation,
Human, Xenopus
oocytes, 700 nM,
(Olamendi-
Portugal et al.,
2002)
Voltage-dependent
modulator, Mouse,
Smooth muscle,
EC50 ¼ 365.1 nM, (Zhu
et al., 2009c)
LmaTX3 Lychas mucronatus Inhibit fast
inactivation,
Mouse, HEK293,
EC50 ¼ 4.98 mM,
(Xu et al., 2014)
Inhibit fast
inactivation,
Human, HEK293,
EC50 ¼ 1.23 mM,
(Xu et al., 2014)
Inhibit fast
inactivation,
Human, HEK293,
EC50 ¼ 31.46 mM,
(Xu et al., 2014)
LmaTX5 Lychas mucronatus Inhibit fast
inactivation,
Mouse, HEK293,
EC50 ¼ 4.53 mM,
(Xu et al., 2014)
Inhibit fast
inactivation,
Human, HEK293,
EC50 ¼ 1.03 mM,
(Xu et al., 2014)
Inhibit fast
inactivation,
Human, HEK293,
EC50 ¼ 67.62 mM,
(Xu et al., 2014)
Lqh II Leiurus quinquestriatus
hebraeus
Inhibit
inactivation, Rat -
HEK293,
EC50 ¼ 1.8 nM,
(Chen et al., 2002);
Inhibit
inactivation
(strong), Rat,
HEK293, 5 nM,
(Gilles et al., 2000)
Delay inactivation
and speeds
recovery, Rat,
HEK293,
EC50 ¼ 1.4 nM,
(Chen et al., 2000);
Slow inactivation
and increased
current, Rat,
HEK293, 5 nM,
(Gilles et al., 2000)
Inhibit fast
inactivation and
enhanced slow
inactivation,
Human, HEK293,
EC50 ¼ 12 nM,
(Chen and
Heinemann,
2001)
Inhibit
inactivation,
Human, HEK293,
EC50 ¼ 32 nM,
(Chen et al., 2002)
Lqh III Leiurus quinquestriatus
hebraeus
Inhibit
inactivation, Rat,
HEK293,
EC50 ¼ 342 nM,
(Chen et al., 2002);
Inhibit
inactivation
(weak), Rat,
HEK293, 2 mM,
(Gilles et al., 2000)
Delays
inactivation and
speeds recovery,
Rat, HEK293,
EC50 ¼ 5.4 nM,
(Chen et al., 2000);
Inhibit
inactivation and
increased current,
Rat, HEK293,
Inhibit fast
inactivation and
enhanced slow
inactivation,
Human, HEK293,
EC50 < 2.5 nM,
(Chen and
Heinemann,
2001)
Inhibit
inactivation,
Human, HEK293,
EC50 ¼ 13.6 nM,
(Chen et al., 2002)
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5 nM, (Gilles et al.,
2000)
LqhaIT Leiurus quinquestriatus
hebraeus
Delays inhibition
and speeds
recovery, Rat,
HEK293,
EC50 ¼ 0.5 nM,
(Chen et al., 2000)
Inhibition of fast
inactivation,
Human, HEK293,
EC50 ¼ 33 nM,
(Chen and
Heinemann,
2001)
Lqh6 Leiurus quinquestriatus
hebraeus
Delays inhibition
and increased
current, Rat,
Xenopus oocytes,
1 mM, (Hamon
et al., 2002)
Delays
inhibition,
Human, Xenopus
oocytes, 0.2 mM,
(Hamon et al.,
2002)
Lqh7 Leiurus quinquestriatus
hebraeus
Delays inhibition,
Rat, Xenopus
oocytes, 10 mM,
(Hamon et al.,
2002)
Delays inhibition
and increased
current, Rat,
Xenopus oocytes,
1 mM, (Hamon
et al., 2002)
Delays
inhibition,
Human, Xenopus
oocytes, 0.2 mM,
(Hamon et al.,
2002)
Lqhb1 Leiurus quinquestriatus
hebraeus
Hyperpolarisation
of activation
threshold and
inhibits current,
Xenopus oocytes,
2.5 mM, (Gordon
et al., 2003)
Hyperpolarisation
of activation
threshold and
inhibits current,
Rat, Xenopus
oocytes, 2.5 mM,
(Gordon et al.,
2003)
Hyperpolarisation
of activation
threshold and
inhibits current,
Rat, Xenopus
oocytes, 2.5 mM,
(Gordon et al.,
2003)
Inhibition of
current (minor),
Human, Xenopus
oocytes, 2.5 mM,
(Gordon et al.,
2003)
LqqIT2 Leiurus quinquestriatus
quinquestriatus
Hyperpolarisation
of activation
threshold and
inhibits current,
Xenopus oocytes,
1 mM, (Bosmans
et al., 2005)
MeuNaTxa-1 Mesobuthus eupeus Inhibit
inactivation,
Xenopus oocytes,
EC50 ¼ 1.17 mM,
(Zhu et al., 2012a)
Inhibit
inactivation
(weak), Rat,
Xenopus oocytes,
1 mM, (Zhu et al.,
2012a)
Inhibit
inactivation
(weak), Rat,
Xenopus oocytes,
1 mM, (Zhu et al.,
2012a)
Inhibit
inactivation,Mouse,
Xenopus oocytes,
EC50¼ 3.1 mM, (Zhu et al.,
2012a)
Inhibit
inactivation
(weak), Rat,
Xenopus oocytes,
1 mM, (Zhu et al.,
2012a)
MeuNaTxa-2 Mesobuthus eupeus Inhibit
inactivation,
Xenopus oocytes,
EC50 ¼ 1.22 mM,
(Zhu et al., 2012a)
Inhibit
inactivation, Rat,
Xenopus oocytes,
EC50 ¼ 2.23 mM,
(Zhu et al., 2012a)
MeuNaTxa-4 Mesobuthus eupeus Inhibit
inactivation,
Xenopus oocytes,
EC50 ¼ 0.13 mM,
(Zhu et al., 2012a)
MeuNaTxa-5 Mesobuthus eupeus Inhibit
inactivation,
Xenopus oocytes,
EC50 ¼ 0.28 mM,
(Zhu et al., 2012a)
Inhibit
inactivation
(weak), Rat,
Xenopus oocytes,
1 mM, (Zhu et al.,
2012a)
Inhibit
inactivation
(weak), Rat,
Xenopus oocytes,
1 mM, (Zhu et al.,
2012a)
Inhibit
inactivation
(weak), Human,
Xenopus oocytes,
1 mM, (Zhu et al.,
2012a)
Inhibit inactivation,
Mouse, Xenopus oocytes,
EC50 ¼ 0.79 mM, (Zhu
et al., 2012a)
Inhibit
inactivation
(weak), Rat,
Xenopus oocytes,
1 mM, (Zhu et al.,
2012a)
Mesobuthus eupeus
(continued on next page)
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Table 1 (continued )
Peptide Species DmNav1 (Para) Nav1.1 Nav1.2 Nav1.3 Nav1.4 Nav1.5 Nav1.6 Nav1.7 Nav1.8
MeuNaTxa-
12
Inhibit
inactivation,
Xenopus oocytes,
EC50 ¼ 19.95 nM,
(Zhu et al., 2013)
Inhibit
inactivation, Rat,
Xenopus oocytes,
EC50 ¼ 0.91 mM,
(Zhu et al., 2013)
Inhibit
inactivation
(weak), Rat,
Xenopus oocytes,
10 mM, (Zhu et al.,
2013)
Inhibit
inactivation
(weak), Rat,
Xenopus oocytes,
10 mM, Zhu et al.,
2013)
Inhibit inactivation
(weak), Mouse, Xenopus
oocytes, 10 mM, (Zhu
et al., 2013)
MeuNaTxa-
13
Mesobuthus eupeus Inhibit
inactivation,
Xenopus oocytes,
EC50 ¼ 65.5 nM,
(Zhu et al., 2013)
Inhibit
inactivation, Rat,
Xenopus oocytes,
EC50 ¼ 2.5 mM,
(Zhu et al., 2013)
Inhibit
inactivation
(weak), Rat,
Xenopus oocytes,
10 mM, (Zhu et al.,
2013)
Inhibit
inactivation
(weak), Rat,
Xenopus oocytes,
10 mM, (Zhu et al.,
2013)
Inhibit inactivation
(weak), Mouse, Xenopus
oocytes, 10 mM, (Zhu
et al., 2013)
OD1 Odonthobuthus doriae Inhibit
inactivation,
Xenopus oocytes,
EC50 ¼ 80 nM,
(Jalali et al., 2005)
Inhibit
inactivation, Rat,
Xenopus oocytes,
100 nM,
(Maertens et al.,
2006)
Inhibit fast
inactivation and
hyperpolarise
activation
threshold, Human,
CHO cells,
EC50 ¼ 9.6 nM,
(Durek et al.,
2013)
Inhibit
inactivation,
Human, Xenopus
oocytes, 2 mM,
(Jalali et al.,
2005)
Inhibit fast inactivation
and hyperpolarise
activation threshold,
Human, CHO cells,
EC50 ¼ 30 nM, (Durek
et al., 2013)
Inhibit fast
inactivation and
increases current,
Rat, Xenopus
oocytes,
EC50 ¼ 4.5 nM,
(Maertens et al.,
2006); Inhibit fast
inactivation,
Human, CHO cells,
EC50 ¼ 8 nM,
(Durek et al.,
2013)
Phaiodotoxin Anuroctonus
phaiodactylus
Hyperpolarisation
of activation
threshold,
depolarisation of
inactivation, more
current, Xenopus
oocytes, 2 mM,
(Valdez-Cruz et al.,
2004)
TdVIII Tityus discrepans Hyperpolarisation
of activation
threshold and
inhibit current,
Rat, Xenopus
oocytes, 100 nM,
(Tsushima et al.,
1999)
Tf2 Tityus fasciolatus Hyperpolarisation
of activation
threshold, Human,
Xenopus oocytes,
1 mM, (Camargos
et al., 2015)
TiTx gamma Tityus serrulatus Hyperpolarisation
of activation
threshold, Rat,
Xenopus oocytes,
50 nM, (Marcotte
et al., 1997)
Ts1 Tityus serrulatus Bell-shaping
gating modulator,
HEK293, 100 nM-1
Hyperpolarisation
of activation
threshold, Rat,
Hyperpolarisation
of activation
threshold, Rat,
Hyperpolarisation
of activation
threshold and
Inhibit current,
Human, HEK293,
EC50 ¼ 55 nM,
Hyperpolarisation of
activation threshold and
inhibit current, Mouse,
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mM, (Peigneur
et al., 2015)
HEK293, 100 nM,
(Peigneur et al.,
2015)
HEK293, 100 nM,
(Peigneur et al.,
2015)
inhibit current,
Rat, HEK293,
100 nM, (Peigneur
et al., 2015)
(Peigneur et al.,
2015)
HEK293, 100 nM,
(Peigneur et al., 2015)
Ts2 Tityus serrulatus Inhibit rapid
inactivation, Rat,
Xenopus oocytes,
1 mM, (Cologna
et al., 2012)
Inhibit rapid
inactivation and
hyperpolarisation
of activation
threshold, Rat,
Xenopus oocytes,
1 mM, (Cologna
et al., 2012)
Inhibit rapid
inactivation,
Human, Xenopus
oocytes, 1 mM,
(Cologna et al.,
2012)
Inhibit rapid inactivation,
Mouse, Xenopus oocytes,
1 mM, (Cologna et al.,
2012)
Inhibit rapid
inactivation, Rat,
Xenopus oocytes,
1 mM, (Cologna
et al., 2012)
Ts4 Tityus serrulatus Inhibit fast inactivation,
Xenopus oocytes,
EC50 ¼ 1.19 mM, (Pucca
et al., 2015b)
TsVII Tityus serrulatus Hyperpolarisation
of activation
threshold,
Xenopus oocytes,
5 mM, (Bosmans
et al., 2007)
Hyperpolarisation
of activation
threshold, Rat,
Xenopus oocytes,
5 mM, (Bosmans
et al., 2007)
Tt1g Tityus trivittatus Hyperpolarisation
of activation
threshold, Human,
HEK293, 500 nM,
(Coronas et al.,
2015)
Hyperpolarisation
of activation
threshold, Human,
HEK293, 500 nM,
(Coronas et al.,
2015)
Inhibit current,
Human, HEK293,
500 nM, (Coronas
et al., 2015)
Inhibit current,
Human, HEK293,
500 nM,
(Coronas et al.,
2015)
Tz1 Tityus zulianus Hyperpolarisation
of activation
threshold,
HEK293, 10 mM,
(Leipold et al.,
2006)
Hyperpolarisation
of activation
threshold,
HEK293,
Kd ¼ 3.5 mM,
(Leipold et al.,
2006);
Hyperpolarisation
of activation
threshold, Rat,
HEK293,
EC50 ¼ 3.5 mM,
(Borges et al.,
2004)
Hyperpolarisation of
activation threshold,
HEK293, 10 mM, (Leipold
et al., 2006)
Note: Data represented sequentially as: Action, channel species origin for recombinant expression (if reported), expression system, concentration, reference.
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Table 2
Action of scorpion toxin peptides on Drosophila Shaker Kþ, Kv1 and Kv4-type voltage-gated potassium channels.
Peptide Species Drosophila
Shaker Kþ
Kv1.1 Kv1.2 Kv1.3 Kv1.4 K1.5 Kv1.6 Kv4.1 Kv4.2 Kv4.3
Aa1 Androctonus
australis
Garzoni
Inhibit current,
ShH4, Xenopus,
oocytes,
Kd ¼ 4.5 mM,
(Pisciotta et al.,
1998)
Aam-KTX
(Kaliotoxin
analogue)
Androctonus
amoreuxi
Inhibit current,
Rat, Xenopus
oocytes,
EC50 ¼ 10 nM,
(Abbas et al.,
2008)
Inhibit current, Rat, Xenopus
oocytes, EC50 ¼ 1.1 nM,
(Abbas et al., 2008)
Agitoxin 1
(AgTX 1)
Leiurus
quinquestriatus
hebraeus
Inhibit current,
ShH4, Xenopus
oocytes,
Ki ¼ 0.16 nM,
(Garcia et al.,
1994)
Inhibit current, Rat,
Xenopus oocytes,
Ki ¼ 136 nM, (Garcia
et al., 1994)
Inhibit current, Rat, Xenopus
oocytes, Ki ¼ 1.3 nM, (Garcia
et al., 1994)
Inhibit current,
Xenopus oocytes,
Ki ¼ 149 nM,
(Garcia et al.,
1994)
Agitoxin 2
(AgTX 2)
Leiurus
quinquestriatus
hebraeus
Inhibit current,
ShH4, Xenopus
oocytes,
Ki ¼ 0.64 nM,
(Garcia et al.,
1994)
Inhibit current, Rat,
Xenopus oocytes,
Ki ¼ 44 pM, (Garcia
et al., 1994)
Inhibit current, Rat, Xenopus
oocytes, Ki ¼ 4 pM, (Garcia
et al., 1994)
Inhibit current,
Xenopus oocytes,
Ki ¼ 37 pM,
(Garcia et al.,
1994)
Agitoxin 3
(AgTX 3)
Leiurus
quinquestriatus
hebraeus
Inhibit current,
ShH4, Xenopus
oocytes,
Ki ¼ 0.64 nM,
(Garcia et al.,
1994)
Anuroctoxin a-
KTx 6.12
Anuroctonus
phaiodactylus
Inhibit current,
Rat, CTLL-2,
Kd ¼ 5 nM,
(Bagdany et al.,
2005); Inhibit
current, Human,
Cos-7, Kd ¼ 6 nM,
(Bagdany et al.,
2005)
Inhibit current,H uman T
lymphocytes, Kd ¼ 0.73 nM,
(Bagdany et al., 2005)
BmK86 a-
KTx26.1
Buthus
martensii
Karsch
Inhibit current, Mouse, COS7,
IC50 ¼ 150 nM, (Mao et al.,
2007)
BmKTX Buthus
martensii
Karsch
Inhibit current, Rat, Xenopus
oocytes, IC50 ¼ 0.2 nM, (Romi-
Lebrun et al., 1997)
BmP02 Buthus
martensii
Karsch
Inhibit current,
ShIR, Xenopus
oocytes,
IC50 ¼ 20.4 mM,
(Zhu et al.,
2012b)
Inhibit current, Rat,
Xenopus oocytes,
IC50 ¼ 1.95 mM, (Zhu
et al., 2012b)
Inhibit current,
Rat, Xenopus
oocytes,
IC50 ¼ 4.4 mM,
(Zhu et al., 2012b)
Inhibit current,Rat, Xenopus
oocytes, IC50 ¼ 7 nM, (Zhu
et al., 2012b)
BmP03 Buthus
martensii
Karsch
Inhibit current,
ShIR, Xenopus
oocytes,
IC50 ¼ 4.64 mM,
(Zhu et al.,
2012b)
Inhibit current, Rat,
Xenopus oocytes,
IC50 ¼ 5.48 mM, (Zhu
et al., 2012b)
Inhibit current,
Rat, Xenopus
oocytes,
IC50 ¼ 530 nM,
(Zhu et al., 2012b)
Inhibit current, Rat, Xenopus
oocytes, IC50 ¼ 85.4 nM, (Zhu
et al., 2012b)
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Buthus
martensii
Karsch
Inhibit current, Rat, Xenopus
oocytes, IC50¼ 1.5 nM, (Romi-
Lebrun et al., 1997)
BmTX2 Buthus
martensii
Karsch
Inhibit current, Rat, Xenopus
oocytes, IC50¼ 1.6 nM, (Romi-
Lebrun et al., 1997)
BmTX3 Buthus
martensii
Karsch
Inhibit current,
COS-7,
IC50 ¼ 105 nM,
(Vacher et al.,
2006)
Inhibit
current,
COS-7,
1 mM,
(Vacher
et al.,
2006)
Inhibit current,
COS-7, 300 nM,
(Vacher et al.,
2006)
BoiTx1 a-
KTx3.10
Buthus
occitanus
israelis
Inhibit current,
ShH4, Xenopus
oocytes,
IC50 ¼ 3.5 nM,
(Kozminsky-
Atias et al., 2007)
Bs6 a-KTx3.8 Buthus sindicus Inhibit current, Human,
Xenopus oocytes,
IC50 ¼ 0.89 nM, (Kohl et al.,
2015)
Bs-KTx6 Buthus sindicus Inhibit current, Rat, HEK293,
IC50¼ 7.7 pM, (Ali et al., 2014)
BTK-2 Buthus tamulus Inhibit current,
Human, Xenopus
oocytes,
IC50 ¼ 4.6 mM,
(Dhawan et al., 2003)
Butantoxin a-
KTx12.2
Tityus
trivittatus
Inhibit current,
ShB, Sf9,
Kd ¼ 660 nM,
(Coronas et al.,
2003)
Ce1 a-KTx 2.8 Centruroides
elegans Thorell
Inhibit current, Human T
lymphocytes, ED50 ¼ 0.7 nM,
(Olamendi-Portugal et al.,
2005)
Ce2 a-KTx 2.9 Centruroides
elegans Thorell
Inhibit current,Human T
lymphocytes, ED50 ¼ 0.25 nM,
(Olamendi-Portugal et al.,
2005)
Ce3 a-KTx 2.10 Centruroides
elegans Thorell
Inhibit currentHuman T
lymphocytes,ED50 ¼ 366 nM,
(Olamendi-Portugal et al.,
2005)
Ce4 a-KTx 2.11 Centruroides
elegans Thorell
Inhibit current,Human T
lymphocytes, ED50 ¼ 0.98 nM,
(Olamendi-Portugal et al.,
2005)
Ce5 a-KTx 2.12 Centruroides
elegans Thorell
Inhibit current, Human T
lymphocytes, ED50 ¼ 69 nM,
(Olamendi-Portugal et al.,
2005)
Charbydotoxin
(ChTX)
Leiurus
quinquestriatus
hebraeus
Inhibit current,
ShH4, Xenopus
oocyte,
Kd ¼ 3.6 nM,
Inhibit current,
Xenopus oocyte,
Kd ¼ 1.5 mM, (Garcia
et al., 1994); Inhibit
Inhibit current,
B82, Kd ¼ 1.7 nM
(Werkman et al.,
1992); Inhibit
Inhibit current, Human, CHO,
10 nM, (Nikouee et al., 2012);
Inhibit current, Mouse, L929,
Kd ¼ 2.6 nM, (Grissmer et al.,
Inhibit current,
Human, MEL,
Kd > 100 nM,
Inhibit current,
Xenopus oocytes,
Ki ¼ 22 nM,
(continued on next page)
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Table 2 (continued )
Peptide Species Drosophila
Shaker Kþ
Kv1.1 Kv1.2 Kv1.3 Kv1.4 K1.5 Kv1.6 Kv4.1 Kv4.2 Kv4.3
(MacKinnon
et al., 1988);
Inhibit current,
Xenopus oocytes,
Ki ¼ 227 nM,
(Garcia et al.,
1994)
current, Mouse, L929,
Kd ¼ >1 mM,
(Grissmer et al.,
1994)
current, Xenopus
oocytes,
IC50 ¼ 10 nM,
(Russell et al.,
1994); Inhibit
current, Rat, B82
fibroblast,
Kd > 14 nM,
(Grissmer et al.,
1994)
1994); Inhibit current,
Xenopus oocytes, Ki¼ 0.19 nM,
(Garcia et al., 1994)
(Grissmer et al.,
1994)
(Garcia et al.,
1994)
Cobatoxin 1 a-
KTx 9.1
Centruroides
noxius
Inhibit current,
ShB, Sf9,
Kd ¼ 0.7 mM,
(Selisko et al.,
1998)
Inhibit current,
Mouse, Xenopus
oocytes, Kd ¼ 0.5 mM,
(Selisko et al., 1998)
Inhibit current,
Rat, Mamillian
cells, Kd ¼ 27 nM,
(Jouirou et al.,
2004)
Cobatoxin 2 a-
KTx 9.2
Centruroides
noxius
Inhibit current,
ShB, Sf9 cells,
Kd ¼ 4.1 mM,
(Selisko et al.,
1998)
Inhibit current,
Mouse, Xenopus
oocytes, Kd ¼ 1.0 mM,
(Selisko et al., 1998)
Css20 a-KTx
2.13
Centruroides
suffusus
suffusus
Inhibit current,
Human, Cos7,
Kd ¼ 1.3 nM,
(Corzo et al.,
2008)
Inhibit current, Human
lymphocytes, Kd ¼ 7.2 nM,
(Corzo et al., 2008)
Ctri9577 Chaerilus
tricostatus
Inhibit current, Mouse,
HEK293, IC50 ¼ 0.49 nM, (Xie
et al., 2012)
Inhibit current
and gating
modifier, Rat,
HEK293,
IC50 ¼ 1.34 mM,
(Xie et al., 2014)
Discrepin a-
KTx15.6
Tityus
discrepans
Inhibit
current,HEK293,
IC50 ¼ 234 mM,
(Picco et al.,
2014)
Ev37 Euscorpiops
validus
Inhibit current, Rat, HEK293,
Kd ¼ 0.95 mM, (Feng et al.,
2013)
Hemitoxin Hemiscorpius
lepturus
Inhibit current, Rat,
Xenopus oocytes,
Kd ¼ 13 nM, (Srairi-
Abid et al., 2008)
Inhibit current,
Rat, Xenopus
oocytes,
Kd ¼ 16 nM,
(Srairi-Abid et al.,
2008)
Inhibit current, Rat, Xenopus
oocytes, Kd ¼ 2 nM, (Srairi-
Abid et al., 2008)
HeTx204 Heterometrus
petersii
Inhibit current, HEK293, 1 mM,
(Chen et al., 2012)
HgeTx1 a-
KTx6.1
Hadrurus
gertschi
Inhibit current,
ShB, Sf9,
Kd ¼ 52 nM,
(Schwartz et al.,
2006)
Hl15-1-1 Heterometrus
laoticus
Inhibit current,Ltk,
Kd ¼ 9.9 mM,
(Vandendriessche
et al., 2012)
Inhibit current,
Ltk, 30 mM,
(Vandendriessche
et al., 2012)
HSCTX1
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Heterometrus
spinnifer
Inhibit current, Rat, Xenopus
oocytes, IC50 ¼ 12 pM,
(Lebrun et al., 1997)
ImKTx1 Isometrus
maculatus
Inhibit current,
Mouse, HEK293,
10 mM, (Chen et al.,
2011)
Inhibit current,
Human, HEK293,
10 mM, (Chen
et al., 2011)
Inhibit current, Mouse,
HEK293, IC50 ¼ 1.7 mM, (Chen
et al., 2011)
ImKTx88 Isometrus
maculates
Inhibit current, HEK293,
IC50 ¼ 91 pM, (Han et al.,
2011)
J123 Buthus
martensii
Karsch
Inhibit current (20%),
Human, HEK293,
1 mM, (Shijin et al.,
2008)
Inhibit current,
Human, HEK293,
IC50 ¼ 26.4 nM,
(Shijin et al.,
2008)
Inhibit current, Rat, HEK293,
IC50 ¼ 0.79 nM (Shijin et al.,
2008)
KAaH1 Androctonus
australis Hector
Inhibit current, Rat,
Xenopus oocytes,
IC50 ¼ 5 nM, (Srairi-
Abid et al., 2005)
Inhibit current,
Rat, Xenopus
oocytes,
IC50 ¼ 50 nm,
(Srairi-Abid
et al., 2005)
Kaliotoxin a-
KTx3.1
Androctonus
mauretanicus
mauretanicus
Inhibit current,
Mouse, L929,
Kd ¼ 41 nM,
(Grissmer et al.,
1994)
Inhibit current,
Rat, B82
fibroblast,
Kd > 1 mM,
(Grissmer et al.,
1994)
Inhibit current, Mouse, L929,
Kd ¼ 0.65 nM, (Grissmer et al.,
1994)
Inhibit current,
Human, MEL,
Kd > 1 mM,
(Grissmer et al.,
1994)
Κ-KTx 2.5 Opisthacanthus
cayaporum
Inhibit current,
Human,
CHO,IC50 ¼ 217 mM,
(Camargos et al.,
2011)
Inhibit current,
Human, CHO,
IC50 ¼ 71 mM,
(Camargos
et al., 2011)
Kbot1 Buthus
occitanus
tunetanus
Inhibit current, Rat,
Xenopus oocytes,
IC50 ¼ 145 nM,
(Mahjoubi-Boubaker
et al., 2004)
Inhibit current,
Rat, Xenopus
oocytes,
IC50 ¼ 2.5 nM,
(Mahjoubi-
Boubaker et al.,
2004)
Inhibit current, Rat, Xenopus
oocytes, IC50 ¼ 15 nM,
(Mahjoubi-Boubaker et al.,
2004)
Kbot55 a-
Ktx31.1
Buthus
occitanus
tunetanus
Inhibit current,
Shaker IR,
Xenopus oocytes,
1 mM, (ElFessi-
Magouri et al.,
2015)
LmKTx10 Lychas
mucronatus
Inhibit current,
Mouse, HEK293,
IC50 ¼ 1.73 mM, (Liu
et al., 2009)
Inhibit current,
Human, HEK293,
IC50 ¼ 12.63 mM,
(Liu et al., 2009)
Inhibit current, Mouse,
HEK293, IC50 ¼ 28 nM, (Liu
et al., 2009)
LmKTx8 Lychas
mucronatus
Inhibit current, Mouse, COS7,
IC50 ¼ 26.4 nM, (Wu et al.,
2007)
Margatoxin
(MgTx)
Centruroides
margaritatus
Inhibit current,
ShH4,
IC50 ¼ 150 nM,
Inhibit current,
Human, tsA201 cells,
Kd ¼ 4.2 nM, (Bartok
Human,
tsA201 cells,
Kd ¼ 6.4 pM,
Inhibit current, Human,
tsA201 cells, Kd ¼ 11.7 pM,
(Bartok et al., 2014); Inhibit
Inhibit current,
Rat,
IC50 > 200 nM,
Inhibit ent,
Rat, IC5 5 nM,
(continued on next page)
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Table 2 (continued )
Peptide Species Drosophila
Shaker Kþ
Kv1.1 Kv1.2 Kv1.3 Kv1.4 K1.5 Kv1.6 Kv4.1 Kv4.2 Kv4.3
(Garcia-Calvo
et al., 1993)
et al., 2014); Inhibit
current, Mouse,
L929 cells,
Kd ¼ 1.7 nM, (Bartok
et al., 2014)
(Bartok et al.,
2014)
current, Human T lymphocyte,
Kd ¼ 10.1 pM, (Bartok et al.,
2014); Inhibit current,
IC50 ¼ 30 pM, (Garcia-Calvo
et al., 1993); Inhibit current,
Human, CHO, 10 nM, (Nikouee
et al., 2012)
(Garcia-Calvo
et al., 1993)
(Garcia-Calvo
et al., 1993)
Martentoxin Buthus martensi
Karsch
Inhibit current, Mouse,
HEK293, 1 mM, (Tao et al.,
2014)
Maurotoxin a-
KTx6.2
Scorpio maurus
palmatus
Inhibit current,
ShB, Xenopus
oocytes,
IC50 ¼ 2.4 nM,
(di Luccio et al.,
2002); Inhibit
current, ShB,
Xenopus oocytes,
IC50 ¼ 2 nM,
(Carlier et al.,
2000)
Inhibit current, Rat,
Xenopus oocytes,
IC50 ¼ 45 nM,
(Kharrat et al., 1997);
Inhibit current, Rat,
Xenopus oocytes,
IC50 ¼ 37 nM,
(Kharrat et al., 1996)
Inhibit current,
Rat, Xenopus
oocytes,
IC50 ¼ 0.8 nM,
(Kharrat et al.,
1997); Inhibit
current, Rat,
Xenopus oocytes,
IC50 ¼ 0.8 nM,
(Kharrat et al.,
1996); Inhibit
current, Mouse,
B82,IC50 ¼ 120
pM, (Castle et al.,
2003)
Inhibit current, Rat, Xenopus
oocytes, IC50 ¼ 180 nM,
(Kharrat et al., 1997); Inhibit
current, Rat, Xenopus oocytes,
IC50 ¼ 150 nM, (Kharrat et al.,
1996)
Mesomartoxin Mesobuthus
martensii
Inhibit current,
ShIR, Xenopus
oocytes,
IC50 ¼ 54 pM,
(Wang et al.,
2015)
Inhibit current,
Rat, Xenopus
oocytes,
IC50 ¼ 15.6 nM,
(Wang et al.,
2015)
Inhibit current, Rat, Xenopus
oocytes, IC50 ¼ 12.5 mM,
(Wang et al., 2015)
MeuKTX a-
KTx3.13
Mesobuthus
eupeus
Inhibit current,
ShIR, Xenopus
oocytes, 2 mM,
(Gao et al., 2010)
Inhibit current, Rat,
Xenopus oocytes,
IC50 ¼ 203.15 pM,
(Gao et al., 2010)
Inhibit current,
Rat, Xenopus
oocytes,
IC50 ¼ 8.92 nM,
(Gao et al., 2010)
Inhibit current, Human,
Xenopus oocytes, IC50 ¼ 171
pM, (Gao et al., 2010)
Inhibit current,
Rat, Xenopus
oocytes, 2 mM,
(Gao et al., 2010)
MeuTx3B Mesobuthus
eupeus
Inhibit current, Human,
Xenopus oocytes, 2 mM, (Gao
et al., 2011)
Noxiustoxina-
KTx2.1
Centruroides
noxius
Inhibit current,
Mouse, L929,
Kd > 25 nM,
(Grissmer et al.,
1994)
Inhibit current,
Rat, B82
fibroblast,
Kd ¼ 2 nM,
(Grissmer et al.,
1994)
Inhibit current, Mouse, L929,
Kd ¼ 1 nM, (Grissmer et al.,
1994)
Inhibit current,
Human, MEL,
Kd > 25 nM,
(Grissmer et al.,
1994)
OcyKTx2 a-
KTx6.17
Opisthacanthus
cayaporum
Inhibit current,
ShB, Sf9,
Kd ¼ 82 nM,
(Schwartz et al.,
2013)
Inhibit current, Human T
lymphocytes, Kd ¼ 18 nM,
(Schwartz et al., 2013)
OdK1 a-KTx 8.5 Odonthobuthus
doriae
Inhibit current,
Rat, Xenopus
oocytes,
IC50 ¼ 183 nM,
(Abdel-Mottaleb
et al., 2006a)
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OdK2 a-
KTX3.11
Odonthobuthus
doriae
Inhibit current, Rat, Xenopus
oocytes, IC50 ¼ 7.2 nM,
(Abdel-Mottaleb et al., 2008a)
OSK1 a-KTx3.7 Orthochirus
scrobiculosus
Inhibit current,
Mouse, COS7,
IC50 ¼ 0.6 nM,
(Mouhat et al., 2005)
Inhibit current,
Human, COS7,
IC50 ¼ 5.4 nM,
(Mouhat et al.,
2005)
Inhibit current, Mouse, L929,
IC50 ¼ 14 pM, (Mouhat et al.,
2005)
OSK2 a-KTx
13.2
Orthochirus
scrobiculosus
Inhibit current,
Xenopus oocyte,
Kd ¼ 97 nM,
(Dudina et al.,
2001)
PBTx1 Parabuthus
transvaalicus
Inhibit current,
Xenopus oocyte,
Kd ¼ 21.1 mM, (Huys
et al., 2004b)
Inhibit current,
Rat, Xenopus
oocytes,
Kd ¼ 1.0 mM,
(Huys et al.,
2004b)
Inhibit current, Xenopus
oocyte, Kd ¼ 0.8 mM (Huys
et al., 2004b)
PBTx3 a-
KTx1.10
Parabuthus
transvaalicus
Inhibit current,
Xenopus oocytes,
Kd ¼ 79 mM, (Huys
et al., 2002)
Inhibit current,
Rat, Xenopus
oocytes,
Kd ¼ 547 nM,
(Huys et al., 2002)
Inhibit current, Xenopus
oocytes, Kd ¼ 492 nM, (Huys
et al., 2002)
Pi1 Pandinus
imperator
Inhibit current,
ShB, Xenopus
oocytes,
IC50 ¼ 23 nM,
(Fajloun et al.,
2000a); Inhibit
current, ShB, Sf9,
Kd ¼ 32 nM,
(Gomez-Lagunas
et al., 1997)
Inhibit current,
Rat, Xenopus
oocytes,
IC50 ¼ 0.44 nM,
(Fajloun et al.,
2000a)
Inhibit current, Human T
lymphocytes, Kd ¼ 11.4 nM,
(Peter et al., 2000); Inhibit
current, Human T
lymphocytes, Kd ¼ 9.7 nM,
(Peter et al., 1998)
Pi2 (PiTX-Ka) Pandinus
imperator
Inhibit current,
ShB, Sf9,
Kd ¼ 8.2 nM,
(Gomez-Lagunas
et al., 1996)
Inhibit current,
B82, IC50 ¼ 32
pM, (Rogowski
et al., 1996)
Inhibit current, Human T
lymphocytes, Kd ¼ 50 pM,
(Peter et al., 2000;Peter et al.,
1998)
Pi3 (PiTX-Kb) Pandinus
imperator
Inhibit current,
ShB, Sf9,
Kd ¼ 140 nM,
(Gomez-Lagunas
et al., 1996)
Inhibit current, Human T
lymphocytes, Kd ¼ 0.5 nM,
(Peter et al., 2000;Peter et al.,
1998)
Pi4 Pandinus
imperator
Inhibit current,
ShB, Xenopus
oocytes,
IC50 ¼ 3 nM,
(M'Barek et al.,
2003); Inhibit
current, ShB, Sf9,
Kd ¼ 8 nM,
(Olamendi-
Portugal et al.,
1998)
Inhibit current,
Rat, Xenopus
oocytes, IC50 ¼ 8
pM, (M'Barek
et al., 2003)
SjAPI-2 Scorpiops
jendeki
Inhibit current,
Mouse, HEK293,
1 mM, (Chen et al.,
2015)
Inhibit current,
HEK293, 1 mM,
(Chen et al., 2015)
Inhibit current, Mouse,
HEK293, 1 mM, (Chen et al.,
2015)
StKTx23 Scorpiops
jendeki
Inhibit current, HEK293, 1 mM,
(Chen et al., 2012)
Tamulustoxin
(continued on next page)
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Table 2 (continued )
Peptide Species Drosophila
Shaker Kþ
Kv1.1 Kv1.2 Kv1.3 Kv1.4 K1.5 Kv1.6 Kv4.1 Kv4.2 Kv4.3
Mesobuthus
tamulus
Inhibit current,
Human, CHO,
500 nM, (Strong
et al., 2001)
Tc1 Tityus
cambridgei
Inhibit current,
ShB, Sf9,
Kd ¼ 65 nM,
(Batista et al.,
2000)
Tc Tityus
cambridgei
Inhibit current,
ShB, SF9,
Kd ¼ 4.7 mM,
(Batista et al.,
2002)
Inhibit current, Human T
lymphocyte, Kd ¼ 16 nM,
(Batista et al., 2002);
Tc32 Tityus
cambridgei
Inhibit current,
ShB, SF9,
Kd ¼ 74 nM,
(Batista et al.,
2002)
Inhibit current, Human T
lymphocyte, Kd ¼ 10 nM,
(Batista et al., 2002); Inhibit
current, Mouse olfactory bulb
and peri-glomerular cells,
1 mM, (Stehling et al., 2012)
TdK1 a-KTx4.3 Tityus
discrepans
Inhibit current,
ShB, SF9,
Kd ¼ 280 nM,
(D'Suze et al.,
1999)
Ts15a-Ktx21.1 Tityus
serrulatus
Inhibit current,
ShIR, Xenopus
oocytes, 0.5 mM,
(Cologna et al.,
2011)
Inhibit current,
Rat, Xenopus
oocytes,
IC50 ¼ 196 nM,
(Cologna et al.,
2011)
Inhibit current, Human,
Xenopus oocytes,
IC50 ¼ 508 nM, (Cologna et al.,
2011)
Inhibit current,
Rat, Xenopus
oocytes, 0.5 mM,
(Cologna et al.,
2011)
Ts19 Frag-II Tityus
serrulatus
Inhibit current,
Xenopus oocytes,
IC50 ¼ 544 nM,
(Cerni et al., 2015)
Ts6 (TSCTX-IV)
a-KTx12.1
Tityus
serrulatus
Inhibit current,
ShIR, Xenopus
oocytes, 1 mM,
(Cerni et al.,
2014)
Inhibit current, Rat,
Xenopus oocytes,
1 mM, (Cerni et al.,
2014)
Inhibit current,
Rat, Xenopus
oocytes,
IC50 ¼ 6.19 nM,
(Cerni et al., 2014)
Inhibit current, Rat, Xenopus
oocytes, IC50 ¼ 0.55 nM,
(Cerni et al., 2014)
Inhibit current,
Rat, Xenopus
oocytes, 1 mM,
(Cerni et al.,
2014)
Inhibit current,
Rat, Xenopus
oocytes, 1 mM,
(Cerni et al., 2014)
Inhibit current,
Rat, Xenopus
oocytes, 1 mM,
(Cerni et al.,
2014)
Ts7 (TSCTX-Ka)
a-KTx4.1
Tityus
serrulatus
Inhibit current,
ShIR, Xenopus
oocytes, 1 mM,
(Cerni et al.,
2014)
Inhibit current, Rat,
Xenopus oocytes,
1 mM, (Cerni et al.,
2014)
Inhibit current,
CL1023,
Kd ¼ 0.21 nM,
(Werkman et al.,
1993); Inhibit
current, Rat,
Xenopus oocytes,
1 mM, (Cerni et al.,
2014)
Inhibit current, Mouse,
Xenopus oocytes, Kd ¼ 3.9 nM,
(Rodrigues et al., 2003); Inhibit
current, Mouse, L929,
Kd¼ 198 nM, (Rodrigues et al.,
2003); Inhibit current, Rat,
Xenopus oocytes, 1 mM, (Cerni
et al., 2014)
Inhibit current,
Rat, Xenopus
oocytes, 1 mM,
(Cerni et al., 2014)
Tst26 a-KTx 4.6 Tityus
stigmurus
Inhibit current,
Human, COS7,
Kd ¼ 1.9 nM,
(Papp et al., 2009)
Inhibit current, Human T
lymphocyte, Kd ¼ 10.7 nM,
(Papp et al., 2009)
TstbKTx Tityus
stigmurus
Inhibit current, Rat,
Xenopus oocytes,
Kd ¼ 96 nM, (Diego-
Garcia et al., 2008)
Inhibit current,
Rat, Xenopus
oocytes, 300 nM,
Inhibit current, Rat, Xenopus
oocytes, 300 nM (Diego-Garcia
et al., 2008)
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(Diego-Garcia
et al., 2008)
Tt28a-KTx20.1 Tityus
trivittatus
Inhibit current,
Rat, Xenopus
oocytes,
Kd ¼ 102.76 nM,
(Abdel-Mottaleb
et al., 2006b)
Inhibit current, Rat, Xenopus
oocytes, Kd ¼ 7.9 nM, (Abdel-
Mottaleb et al., 2006b)
Urotoxin a-
KTx-6.21
Urodacus
yaschenkoi
Inhibit current,
Human, CHO,
IC50 ¼ 253 nM,
(Luna-Ramirez et al.,
2014)
Inhibit current,
Human, CHO,
IC50 ¼ 160 pM,
(Luna-Ramirez
et al., 2014)
Inhibit current, Human,
CHO,IC50 ¼ 91 nM, (Luna-
Ramirez et al., 2014)
Vm24 a-KTx
23.1
Vaejovis
mexicanus
smithi
Inhibit current,
Mouse, L929 cells,
Kd ¼ 30e40 nM,
(Varga et al., 2012)
Inhibit current,
Human, COS7,
Kd ¼ 5e10 nM,
(Varga et al.,
2012)
Inhibit current, Human T
lymphocytes, Kd ¼ 3 pM,
(Gurrola et al., 2012); Inhibit
current, Human T
lymphocytes, Kd ¼ 2.9 pM,
(Varga et al., 2012)
a-KTx 2.14 Rhopalurus
garridoi
Inhibit current,
Human, CHO,
IC50 ¼ 1 mM,
(Rodriguez-Ravelo
et al., 2014)
k-Hefutoxin 1 Heterometrus
fulvipes
Inhibit current,
Rat, Xenopus
oocytes,
Kd ¼ 150 mM,
(Srinivasan et al.,
2002)
Inhibit current and delay
activation, Rat, Xenopus
oocytes,Kd ¼ 40 mM,
(Srinivasan et al., 2002)
l-MeuKTx-1 Mesobuthus
eupeus
Inhibit current,
ShIR, Xenopus
oocytes,
IC50 ¼ 12.3 mM,
(Gao et al., 2013)
a-KTx 10.4 (II-
10.4)
Centruroides
tecomanus
Inhibit current,
Human, tsA201,
IC50 ¼ 3.6 nM,
(Olamendi-
Portugal et al.,
2016)
Inhibit current, Human T
lymphocytes, IC50 ¼ 72 nM,
(Olamendi-Portugal et al.,
2016)
a-KTx 2.15 (II-
10.5)
Centruroides
tecomanus
Inhibit current,
ShIR, tsA201,
IC50 ¼ 8.3 nM,
(Olamendi-
Portugal et al.,
2016)
Inhibit current,
Human, tsA201,
IC50 ¼ 0.3 nM,
(Olamendi-
Portugal et al.,
2016)
Inhibit current, Human T
lymphocytes, IC50 ¼ 8.3 nM,
(Olamendi-Portugal et al.,
2016)
a-KTx 2.16
(II-12.5)
Centruroides
tecomanus
Inhibit current,
Human, tsA201,
IC50 ¼ 0.7 nM,
(Olamendi-
Portugal et al.,
2016)
Inhibit current, Human T
lymphocytes, IC50 ¼ 26.2 nM,
(Olamendi-Portugal et al.,
2016)
a-KTx 2.17 (II-
12.8)
Centruroides
tecomanus
Inhibit current,
Human, tsA201,
IC50 ¼ 4.8 nM,
(Olamendi-Portugal
et al., 2016)
Inhibit current,
Human, tsA201,
IC50 ¼ 2.9 nM,
(Olamendi-
Portugal et al.,
2016)
Note: Data represented sequentially as: Action, channel species origin for recombinant expression (if reported), expression system, concentration, reference.
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Table 3
Action of scorpion toxin peptides on ERG, Kv7, and Kir-type voltage-gated potassium channels.
Peptide Species ERG1 (Kv11.1) ERG2 (Kv11.2) ERG3 (Kv11.3) Kv7.1 Kv7.2 Kv7.2/3 Kv7.3 Kv7.4 Kir1.1
AaTXKb(2e64) Androctonus
australis
Hyperpolarisation
activation
threshold and
increased current,
CHO, 20 mg/ml,
(Landoulsi et al.,
2013)
Hyperpolarisation
activation
threshold and
increased current,
CHO, 20 mg/ml,
(Landoulsi et al.,
2013)
Hyperpolarisation
activation
threshold and
increased current,
Xenopus
oocyte þ CHO,
20 mg/ml,
(Landoulsi et al.,
2013)
AmmTx3 Androctonus
mauretanicus
mauretanicus
Inhibit current,
Human, Xenopus
oocytes,
IC50 ¼ 7.9 mM,
(Abdel-Mottaleb
et al., 2008b)
BeKm-1 Buthus eupeus Inhibit current,
Human, CHO,
Kd ¼ 7.7 nM,
(Restano-Cassulini
et al., 2006); Inhibit
current, Rat, CHO,
Kd ¼ 19 nM,
(Restano-
Cassulini et al.,
2006)
Inhibit current,
Human, HEK293,
IC50 ¼ 3.3 nM,
(Korolkova et al.,
2001); Inhibit
current, Human,
HEK293,
Kd ¼ 9.7 nM,
(Milnes et al., 2003)
Inhibit current,
Human, CHO,
Kd ¼ 77 nM,
(Restano-Cassulini
et al., 2006); Inhibit
current, Rat, CHO,
Kd ¼ 4.2 nM,
(Restano-Cassulini
et al., 2006)
Inhibit current,
Human, CHO,
Kd ¼ 11.5 nM,
(Restano-Cassulini
et al., 2006); Inhibit
current, Rat, CHO,
Kd ¼ 747 nM,
(Restano-Cassulini
et al., 2006)
BmTx3 Bunthus
martensii
Karsch
Inhibit current,
Human, Xenopus
oocyte, Kd¼ 1.9 mM,
(Huys et al., 2004a)
CeErg4
Y-KTx1.7
Centruroides
elegans elegans
Inhibit current,
Human, CHO,
Kd ¼ 12.8 nM,
(Restano-Cassulini
et al., 2008); Inhibit
current,
Rat, CHO,
Kd ¼ 9.9 nM,
(Restano-Cassulini
et al., 2008)
Inhibit current, Rat,
CHO, Kd ¼ 1.45 nM,
(Restano-Cassulini
et al., 2008)
Inhibit current,
Human, CHO,
Kd ¼ 0.866 nM,
(Restano-Cassulini
et al., 2008)
CeErg5
Y-KTx1.8
Centruroides
elegans elegans
Inhibit current,
Human, CHO,
Kd ¼ 9.9 nM,
(Restano-Cassulini
et al., 2008); Inhibit
current, Rat, CHO,
Kd ¼ 12.8 nM,
(Restano-Cassulini
et al., 2008)
Inhibit current, Rat,
CHO, Kd ¼ 1.45 nM,
(Restano-Cassulini
et al., 2008)
Inhibit current,
Human, CHO,
Kd ¼ 0.866 nM,
(Restano-Cassulini
et al., 2008)
ErgTx1
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Centruroides
noxius
Inhibit current,
Human, CHO,
Kd ¼ 4.5 nM,
(Restano-Cassulini
et al., 2006); Inhibit
current, Rat, CHO,
Kd ¼ 6.8 nM,
(Restano-Cassulini
et al., 2006)
Inhibit current, Rat,
CHO, Kd ¼ 2.8 nM,
(Restano-Cassulini
et al., 2006)
Inhibit current,
Human, CHO,
Kd ¼ 4.05 nM,
(Restano-Cassulini
et al., 2006); Inhibit
current, Rat, CHO,
Kd ¼ 38.1 nM,
(Restano-Cassulini
et al., 2006)
HeTx204 Heterometrus
petersii
Inhibit current,
HEK293, 10 mM,
(Chen et al., 2012)
ImKTx104 Isometrus
maculatus
Inhibit current,
HEK293,
Kd ¼ 11.69 mM,
(Chen et al., 2012)
Lq2 Leiurus
quinquestriatus
var. Hebraeus
Inhibit current,
Xenopus oocytes,
Ki ¼ 0.41 mM, (Lu
and MacKinnon,
1997)
SjAPI-2 Scorpiops
jendeki
Inhibit current,
HEK293,
IC50 ¼ 771.5 nM,
(Chen et al., 2015)
Ts6 (TSCTX-IV)
a-KTx12.1
Tityus serrulatus Inhibit current,
Human, Xenopus
oocyte, 1 mM, (Cerni
et al., 2014)
Inhibit current, Rat,
Xenopus oocyte,
1 mM, (Cerni et al.,
2014)
Inhibit current, Rat,
Xenopus oocyte,
1 mM, (Cerni et al.,
2014)
Inhibit current, Rat,
Xenopus oocyte,
1 mM, (Cerni et al.,
2014)
g-KTx 1.9
(II-10.9)
Centruroides
tecomanus
Inhibit Current,
Human,
tsA201,
IC50 ¼ 16.9 nM
Note: Data represented sequentially as: Action, channel species origin for recombinant expression (if reported), expression system, concentration, reference.
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Table 4
Action of scorpion toxin peptides on calcium-activated potassium channels.
Peptide Species BK Channels IK (KCa3$1/KCNN4) Channel SK1 SKCa2 SKCa3
BmBKTx1 Buthus martensii Karsch Inhibit current, Cockroach pSlo,
HEK293, Kd ¼ 82 nM, (Xu et al., 2004);
Inhibit current, Fruit-fly dSlo, HEK293,
Kd ¼ 194 nM, (Xu et al., 2004)
BmP09 Buthus martensii Karsch Inhibit current, Mouse mSlo1, Xenopus
oocytes, EC50¼ 27 nm, (Yao et al., 2005)
Charbydotoxin
(ChTX)
Leiurus quinquestriatus
hebraeus
Inhibit current, Rat, Phospholipid
bilayers, Kd ¼ 10 nM, (Miller et al.,
1985); Inhibit current, Rabbit PCT,
IC50¼ 7.3 nM, (Tauc et al., 1993); Inhibit
current, Snail ganglion, Kd ¼ 20 nM,
(Crest et al., 1992); Inhibit current,
hSlo(a) Human, Xenopus oocytes,
EC50 ¼ 30.8 nM, (Gribkoff et al., 1996)
Inhibit current, Human RBC,
ID50 ¼ 4.2 nM, (Brugnara et al.,
1993); Inhibit current, HEK293,
IC50 ¼ 28 nM, (Jensen et al.,
1998); Inhibit current, Bovine
BAEC, IC50 ¼ 3.3 nM, (Cai et al.,
1998), Inhibit current, Bovine
BAEC, IC50 ¼ 3.3 nM, (Cai et al.,
1998)
Iberiotoxin
(IbTX)
Buthus tamulus Inhibit current, Rabbit PCT, Kd¼ 0.5 mM,
(Tauc et al., 1993); Inhibit current,
Bovine aortic smooth muscle,
IC50 ¼ 250 pM, (Galvez et al., 1990);
Inhibit current, Mouse mSlo1, Xenopus
oocytes, EC50 ¼ 9.1 nM, (Gribkoff et al.,
1996); Inhibit current, Human gBK,
U251 glioma cells, 100 nM, (Tao et al.,
2011); Inhibit current, Human hSlo(a),
Xenopus oocytes, EC50 ¼ 7.9 nM,
(Gribkoff et al., 1996)
Kaliotoxin
(KTX)
Androctonus mauretanicus
mauretanicus
Inhibit current, Rabbit PCT,
IC50 ¼ 0.48 mM, (Tauc et al., 1993);
Inhibit current, Snail ganglion,
Kd ¼ 20 nM, (Crest et al., 1992)
Margatoxin
(MgTx)
Centruroides margaritatus Inhibit current, Human,
HEK293, IC50 ¼ 459 nM, (Jensen
et al., 1998); Inhibit current,
Bovine BAEC, 100 nM, (Cai et al.,
1998)
Martentoxin Buthus martensii Karsch Inhibit current, Rat, Adrenal medulla
chromafin cells, IC50 ¼ 21 nM, (Ji et al.,
2003); Enhanced current, Human gBK,
U251 glioma, EC50¼ 46.7 nM, (Tao et al.,
2011); Enhanced current, Human BK
(hSloa þ b1), Xenopus oocytes,
EC50¼ 495 nM, (Tao et al., 2011); Inhibit
current, Human BK (hSloa þ b4),
IC50 ¼ 80 nM, (Shi et al., 2008); Inhibit
current, Human BK (hSloa þ b4),
HEK293, IC50 ¼ 186 nM, (Tao et al.,
2014)
Maurotoxina-
KTx6.2
Scorpio maurus palmatus Inhibit current, Human RBC,
IC50 ¼ 50 nM, (Castle et al.,
2003); Inhibit current, Human,
CHO, IC50 ¼ 1.1 nM, (Castle
et al., 2003)
Inhibit current,
Human, Jurkat,
Kd ¼ 1 mM,
(Shakkottai et al.,
2001)
Inhibit current,
Human, COS7,
Kd ¼ >1 mM,
(Shakkottai et al.,
2001)
OSK1a-KTx3.7 Orthochirus scrobiculosus
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Inhibit current, Human, tsA,
IC50 ¼ 225 nM, (Mouhat et al.,
2005)
Pi1 Pandinus imperator Inhibit current,
Human, Jurkat,
Kd ¼ 100 nM,
(Shakkottai et al.,
2001)
Inhibit current,
Human, COS7,
Kd ¼ 250 nM,
(Shakkottai et al.,
2001)
PO1 Androctonus mauretanicus
mauretanicus
Inhibit current,
Human, Jurkat, Kd¼
>1 mM, (Shakkottai
et al., 2001)
Inhibit current,
Human, COS7, Kd ¼
>1 mM, (Shakkottai
et al., 2001)
PO5 Androctonus mauretanicus
mauretanicus
Inhibit current,
Human, Jurkat,
Kd ¼ 22 nM,
(Shakkottai et al.,
2001)
Inhibit current,
Human, COS7,
Kd ¼ 25 nM,
(Shakkottai et al.,
2001)
SjAPI-2 Scorpiops jendeki Inhibit current, Human,
HEK293, 1 mM, (Chen et al.,
2015)
Inhibit current, Rat,
HEK293, 1 mM,
(Chen et al., 2015)
Inhibit current,
Human, HEK293,
1 mM, (Chen et al.,
2015)
Slotoxina
KTx1.11
Centruroides noxius
Hoffmann
Inhibit current, Human
hSlo(a), Xenopus oocytes, Kd ¼ 1.5 nM,
(Garcia-
Valdes et al., 2001); Inhibit
current with delayed action,
Human BK (hSloa þ b1), Xenopus
oocytes, 100 nM, (Garcia-Valdes et al.,
2001); Inhibit current with
delayed action, Human BK
(hSloaþ b4), 1 mM, (Garcia-Valdes et al.,
2001)
Scyllatoxin
(Leiurotoxin)
aKTx5.1
Leiurus quinquestriatus
hebraeus
Inhibit current,
Human, Jurkat,
Kd ¼ 0.2 nM,
(Shakkottai et al.,
2001)
Inhibit current,
Human, COS7,
Kd ¼ 1.1 nM,
(Shakkottai et al.,
2001)
Tamapin Mesobuthus tamulus Inhibit current,
Human, CHO,
IC50 ¼ 32 nM,
(Pedarzani
et al., 2002)
Inhibit current, Rat,
HEK293, IC50 ¼ 24
pM, (Pedarzani
et al., 2002)
Inhibit current, Rat,
HEK293,
IC50 ¼ 1.7 nM,
(Pedarzani et al.,
2002)
Ts6 (TSCTX-IV)
a-KTx12.1
Tityus serrulatus Inhibit current, Mouse Leydig, 50 nM,
(Novello et al., 1999)
Tsk Tityus serrulatus Inhibit current, Human,
HEK293, IC50 ¼ 70 nM, (Luna-
Ramirez et al., 2014)
Inhibit current,
Human, Jurkat,
Kd ¼ 80 nM,
(Shakkottai et al.,
2001)
Inhibit current,
Human, COS7,
Kd ¼ 197 nM,
(Shakkottai et al.,
2001)
Urotoxina-KTx-
6.21
Urodacus yaschenkoi Inhibit current, Human,
HEK293, IC50 ¼ 70 nM, (Luna-
Ramirez et al., 2014)
Vm24a-KTx
23.1
Vaejovis mexicanus smithi Inhibit current, Human, COS7,
Kd ¼ 14e30 nM, (Varga et al.,
2012)
Note: Data represented sequentially as: Action, channel species origin for recombinant expression (if reported), expression system, concentration, reference.
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Table 5
Action of scorpion toxin peptides on Cav3 and RYR calcium channels and CFTR and CIC chloride channels.
Peptide Species Cav3.1 (a1G) Cav3.2 (a1H) Cav3.3 (a1I) RyR1 RyR2 RyR3 CFTR Cl channel CIC-2 Cl channel
BjTx-1 Buthotus
judaicus
Increased opening
probability, Pig, Planar
lipid bilayers, 1 mM, (Zhu
et al., 2004);
Subconductance state, Pig,
Planar lipid bilayers, 5 mM,
(Zhu et al., 2004)
BjTx-2 Buthotus
judaicus
Increased opening
probability, Pig, Planar
lipid bilayers, 1 mM, (Zhu
et al., 2004);
Subconductance state, Pig,
Planar lipid bilayers, 5 mM,
(Zhu et al., 2004)
Hadrucalcin
(HdCa)
Hadrurus
gertschi
Subconductance state,
Rabbit, Planar lipid
bilayers, 100 nM, (Xiao
et al., 2016);
Subconductance state,
Rabbit, Planar lipid
bilayers, 30 nM, (Schwartz
et al., 2009)
Subconductance
state, Mouse, Planar
lipid bilayers, 50 nM,
(Schwartz et al.,
2009)
Hemicalcin
(HmCa)
Hemiscorpius
lepturus
Subconductance state,
Rabbit, Planar lipid
bilayers, 100 nM, (Xiao
et al., 2016);
Subconductance state,
Rabbit, 175 nM,
(Shahbazzadeh et al.,
2007)
GaTx1 Leiurus
quinquestriatus
hebraeus
Inhibit current,
Xenopus oocytes,
Kd ¼ 41.5 nM,
IC50 ¼ 48 nM,
(Fuller et al., 2007)
GaTx2 Leiurus
quinquestriatus
hebraeus
Inhibit current,
Rabbit, Xenopus
oocytes, Kd ¼ 22
pM, (Thompson
et al., 2009)
Imperacalcin
(IpCa)
(Imperatoxin
A
(IpTxa))
Pandinus
imperator
Subconductance state,
Rabbit,
Planar lipid bilayers,
100 nM, (Xiao et al., 2016);
Subconductance state,
Rabbit, Lipid bilayers,
15 nM, (Tripathy et al.,
1998); Subconductance
state, Mice, Lipid bilayers,
100 nM, (Nabhani et al.,
2002); Increases opening
and activity, Rabbit, Lipid
bilayer, ED50 ¼ 10 nM, (el-
HayekRet al, 1995)
Subconductance
state, Canine, Lipid
bilayers, 15 nM,
(Tripathy et al., 1998)
Subconductance
state, Mice, Lipid
bilayers, 100 nM,
(Nabhani et al.,
2002)
Kurtoxin
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Parabuthus
transvaalicus
Depolarisation of
activation
threshold and
inhibit current,
Rat, Xenopus
oocytes,
Kd ¼ 15 nM,
(Chuang et al.,
1998)
Depolarisation of
activation threshold
and inhibit current,
Human, Xenopus
oocytes, Kd ¼ 61 nM,
(Chuang et al., 1998)
Kurtoxin-like I
(KLI)
Parabuthus
granulatus
Depolarisation of
activation
threshold and
weakly inhibits
current, Rat,
Xenopus oocytes,
700 nM,
(Olamendi-
Portugal et al.,
2002)
Maurocalcin
(MCa)
Scorpio maurus
palmatus
Subconductance state,
Rabbit, Planar lipid
bilayers, 100 nM, (Xiao
et al., 2016);
Subconductance state,
Planar lipid bilayers,
50 nM, (Fajloun et al.,
2000b)
Opicalcin 1
(OpCa1)
Opistoph
thalmus
carinatus
Subconductance state,
Rabbit,
Planar lipid
bilayers, 100 nM, (Xiao
et al., 2016)
Opicalcin 2
(OpCa2)
Opisto
phthalmus
carinatus
Subconductance state,
Rabbit, Planar lipid
bilayers, 100 nM, (Xiao
et al., 2016)
Ryanotoxin Buthotus
judiacus
Subconductance
state, Rabbit, Skeletal
Muscle SR, ED50
¼
0.16 mM,
(Morrissette et al.,
1996)
Urocalcin
(UrCa)
Urodacus
yaschenkoi
Subconductance
state, Rabbit,
Planar lipid bilayers,
1 mM, (Xiao et al., 2016)
Vejocalcin
(VrCa)
Vaejovis
mexicanus
Subconductance state,
Rabbit, Planar lipid
bilayers, 100 nM, (Xiao
et al., 2016)
4-LITX-Lw1a Liocheles
waigiensis
Excitatory
increasing opening
probability and time in the
open state with
reduced closed time,
Rabbit, lipid bilayer,
AC50 ¼ 6.0 pM, (Smith
et al., 2013)
Excitatory
increasing opening
probability and time
in the open state with
reduced
closed time, Sheep,
lipid bilayer,
AC50¼ 2.0 pM, (Smith
et al., 2013)
(continued on next page)
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D.M. Housley et al. / Neuropharmacology 127 (2017) 46e7872potency and specificity. The specificity of these peptides on Kv1.1 is
uncertain as the majority of studies have had limited testing across
subclasses. KAaH1 appears to be selective for Kv1.1, with an IC50 of
5 nM compared to Kv1.4 with an IC50 of 50 nM (Srairi-Abid et al.,
2005). Margatoxin (Centruroides margaritatus) has the greatest af-
finity for Kv1.2 (Kd ¼ 5.4 pM) but is not selective, also acting on
Kv1.1 and Kv1.3 channels (Bartok et al., 2014). Urotoxin (Urodacus
yaschenk) appears particularly specific for Kv1.2 (IC50 ¼ 160 pM)
compared to Kv1.1 (IC50 ¼ 253 nM) or Kv1.3 (IC50 ¼ 91 nM) (Luna-
Ramirez et al., 2014). The most specific inhibitor of Kv1.3 is the
peptide Vm24 (Vaejovis mexicanus smithi), with a Kd of 2.9 pM
compared to 30e40 nM and 5e10 nM for Kv1.1 and Kv1.2 respec-
tively, and Kd 14e30 nM for KCa3.1 channels (Varga et al., 2012).
Vm24 has the highest affinity of all the Kv toxins. Another highly
selective Kv1.3 inhibitor is Bs-KTx6 (Buthus sindicus) with an IC50 of
7.7 pM, whereas its action on Nav1.1 and Nav1.2 required applica-
tion of micromolar concentrations. The most specific inhibitor of
Kv1.4 was the peptide k-KTx 2.5 (Opisthacanthus cayaporum);
IC50 ¼ 71 mM. While requiring relatively high concentrations for
effect, it was screened against 12 Kv and 5 Nav channels and was
found to be selective for Kv1.4, as well as having minor action on
Kv1.1 (IC50 ¼ 217 mM) (Camargos et al., 2011). In contrast no
particularly specific blockers of Kv1.5 or Kv1.6 have been identified
to date. Tamulustoxin (Mesobuthus tamulus) acts on Kv1.6 at
500 nM (Strong et al., 2001), but selectivity against other channels
has not been determined. BmTX3 (Buthus martensii Karsch) appears
to be selective for Kv4 channels, showing preference for Kv4.1
acting with an IC50 of 105 nM (Vacher et al., 2006).
Table 3 summarizes SCTX peptide actions on the ERG, Kv7 and
Kir voltage-gated potassium channel families. Seven of these pep-
tides target ERG1-3 channels, of which none were particularly se-
lective between subclasses. BmTx3 was selective for hERG (human
ERG) over a number of other potassium channels, (Kv1.1, Kv1.2,
Kv1.3, KCNQ1 and KCNQ1þmIsK, Kir2.1) but its selectivity between
ERG subclasses has not been assessed (Huys et al., 2004a). The
peptide ErgTx1 (Centruroides noxius) showed some preference for
ERG2 channels (Restano-Cassulini et al., 2006), while peptides
CeErg4 and CeErg5 (Centruroides elegans elegans) showed some
preference for ERG3 channels (Restano-Cassulini et al., 2008). SCTX
peptides were able to discriminate between human and rat ERG
channel isoforms. For example, ErgTx1, CeErg4, and CeErg5 did not
affect the human ERG2 isoform despite action on rat ERG2, and
ErgTx1 had much lower affinity for the rERG3 than the hERG3
isoform. The Kv7 family has very limited reported sensitivity to
SCTXs, where AaTXKb2-64 (Androctonus australis) peptide is
excitatory (Landoulsi et al., 2013). This peptide was shown to be a
subtype-selective activator of Kv7.2/3, Kv7.3, and Kv7.4 ion chan-
nels at a concentration of 20 mg/ml, while not affecting Kv1.1, Kv7.1,
Kv7.2 m and Kv7.5 (Landoulsi et al., 2013). The only peptide re-
ported to block Kir1.1 is Lq2 (Leiurus quinquestriatus var. Hebraeus)
with a Ki of 0.41 mM, a concentration that did not affect IRK1
channels (Lu and MacKinnon, 1997).
3.3. Scorpion toxin peptide action on calcium-activated potassium
channels
Table 4 classifies 20 identified SCTX peptides acting on KCa
channels, with evident capacity to discriminate between big (BKCa),
intermediate (IKCa), and small conductance (SKCa) potassium
channels. Of the 7 peptides that were relatively specific for BKCa,
Iberiotoxin (Buthus tamulus) appears to be one of the most potent
selective inhibitors, generally acting at nanomolar concentrations
(Gribkoff et al., 1996). Slotoxin (Centruroides noxius Hoffmann) also
has one of the highest affinities, with a Kd of 1.5 nM (hSloa) in
Xenopus oocytes (Garcia-Valdes et al., 2001). In addition, study of
D.M. Housley et al. / Neuropharmacology 127 (2017) 46e78 73Slotoxin indicated that the beta subunits were significant effectors,
significantly delaying responses in the presence of either b1 or b4
subunits (Garcia-Valdes et al., 2001). Martentoxin (Buthus martensii
Karsch) was the only peptide to show excitatory effects on human
glioma and hSloa with b1, again showing modulation of action by
the presence of b subunits (Tao et al., 2011).
All SCTX peptides shown to act on IKCa channels are inhibitory.
Maurotoxin (Scorpio maurus palmatus) was one of the most potent
and selective inhibitors, with an IC50 of 1.1 nM for hIKCa in CHO cells,
Castle et al., (2003). At micromolar concentrations it had only
minimal effects on SKCa channels, and did not affect BKCa channels.
Similarly all the peptides acting on SKCa channels were inhibitory.
Tamapin (Mesobuthus tamulus) was the most potent peptide acting
on SKCa channels. It demonstrated remarkable selectivity for SK2
with an IC50 of 24 pM, 1750 fold more sensitive than for SK1 and 30
fold more than SK2 (Pedarzani et al., 2002). In addition it did not
affect the IKCa channel. Scyllatonxin (Leiurus quinquestriatus
hebraeus), also known as Leiurotoxin, was another potent SKCa in-
hibitor and again showed preference for the SK2 channel with a Kd
of 0.2 nM (Shakkottai et al., 2001).3.4. Actions of scorpion peptides on calcium channels and chloride
channels
Fewer SCTX peptides are able to modulate calcium or chloride
channels (Table 5), with only 16 peptides affecting calcium chan-
nels, 8 of which were identified in 2016 (Xiao et al., 2016), while 2
SCTX peptides modulate chloride channels. SCTXs have inhibitory
effects on Cav3.1e3.3 channels, depolarising the activation
threshold and decreasing current flow.
Kurtoxin (Parabuthus transvaalicus) was found to selectively
inhibit Cav3.1 and Cav3.2 with a Kd of 15 nM and 61 nM respectively
without affecting high-voltage activated channels in Xenopus oo-
cytes. Subsequently Kurtoxin has been found to modulate a variety
of Nav channels (Chuang et al., 1998;Zhu et al., 2009c), as well high-
voltage activated calcium channels in rats (Sidach andMintz, 2002).
The scorpion Parabuthus granulatus produces two similar peptides,
Kurtoxin-like II (KLII), which is identical to Kurtoxin, as well as
Kurtoxin-like I (KLI), that weakly blocks Cav3.3 and hNav1.5
channels at 700 nM (Olamendi-Portugal et al., 2002). RyR channels
were modulated by SCTX peptides into long-lived subconductance
states, as well as increasing channel opening probability and
reducing closed time. The SCTX peptide 4-LITX-Lw1a (Liocheles
waigiensis) was remarkably potent, affecting RyR1 and RyR2 at
femtomolar concentrations, and had an AC50 of 6.0 pM and 2.0 pM
(Smith et al., 2013). A number of calcins have recently been shown
to affect RyR1, but not yet been yet been screened against other RyR
and calcium channel subtypes to determine their selectivity.
Imperacalcin (Pandinus imperator) is the only identified scorption
RyR3 modulator, inducing a subconductance state when applied at
100 nM, but it also able to potently modulate RyR1 and RYR2
channels (Nabhani et al., 2002).
The only peptide found to modulate the CFTR chloride channel
was GaTx1 (Leiurus quinquestriatus hebraeus), which had an IC50 of
48 nM (Fuller et al., 2007). This peptide appears highly specific and
was shown to have no effect on a panel of nine transport proteins
including chloride, potassium and the ABC families (Fuller et al.,
2007). GaTx2 (Leiurus quinquestriatus hebraeus) is the only pep-
tide discovered to inhibit CIC chloride channels. GaTx2 was found
to specifically inhibit the CIC-2 channel with a Kd of 22 pM
(Thompson et al., 2009). This peptide was highly specific and did
not affect CIC-1, CIC3-4, CFTR, or a number of other chloride and
potassium channels (Thompson et al., 2009).4. Discussion
This review provides a comprehensive analysis of specific
functionally validated SCTX peptide actions across ion channel
subclasses. The information provided by the analysis is intended to
be of sufficient detail to allow informed comparison of toxin effects
across differing channel types and expression systems. In addition,
the review provides a substantial data resource to highlight the
breadth of specific SCTX peptides and also serves to draw attention
to areas of SCTX research where the knowledge base is limited by
the lack of comparison across ion channel types. This review will
also assist to reduce redundancy of research where replication of
findings is robust, and conversely, identifies areas of characteriza-
tion where replication is needed to improve the validation of
functionality.
Advances in molecular techniques over the last two decades
have significantly revolutionised the experimental approaches
used to assess SCTX action on ion channels. Early publications
within the field typically examined the effects of poorly defined
crude venom on net membrane current flux, and then moved to
isolating and examining the function of novel peptides within this
mixture. Likely ion channel targets were identified by structural
comparison of these peptides to other peptides with known action,
allowing more directed research, reducing the need for toxin pu-
rification, lowering costs, and saving time. However this reduc-
tionist approach likely impacted on the breadth of screening for
SCTX effects, limiting identification of peptide selectivitiy across ion
channel subfamilies. Our analysis indicates that the number of
studies prioritising the identification of specific molecular targets
using isolated and well-defined peptide fragments has steadily
increased overtime. The development of recent techniques such as
site-directed mutagenesis, production of recombinant toxin vari-
ants and chimeric ion channel constructs, together with use of
improved 3D modelling, has allowed greater understanding of
toxin-channel interactions and the underlying mechanisms deter-
mining the SCTX selectivity and affinity (Gilchrist and Bosmans,
2012;Zhang et al., 2011, 2012;Gur et al., 2011;Gurevitz, 2012;Ma
et al., 2013). Use of cloned ion channels within expression sys-
tems has been central to study of SCTX peptide action. Xenopus
oocytes were identified as the most commonly used expression
system, with mammalian cell lines such as HEK293 and CHO also
prevalent. One pertinent example involving mutagenesis was the
study of SCTX ErgTx1 (Centruroides noxius) to analyse interactions
with human ERG Kþ channels, using CHO cells (Jimenez-Vargas
et al., 2012b).
The need for further researchwithin the field is evident from the
expanding library of SCTX peptides, given that venom from each of
the ~1500 scorpion species is thought to have around 70 peptides,
with only a minority having been functionally assessed (Possani
et al., 1999). There is clear homology of the SCTX peptides across
species that act on specific channel classes. For example, as noted,
Kurtoxin has been isolated from both Parabuthus transvaalicus and
Parabuthus granulatus with potent action on Cav3.1 and Cav3.2
(Chuang et al., 1998;Olamendi-Portugal et al., 2002).
There was signficiant variation within the selectivity displayed
by SCTX peptides, with some appearing to be particularly specific,
while others were promiscuous. Interpretation was made difficult
by a common lack of comprehensive screening against a wide va-
riety of ion channel subfamilies. However, an inverse relationship
between toxin peptide concentration and selectivity was identified
for several SCTX peptides, with peptides tending to have broader
action on ion channel classes when applied in the micromolar, as
opposed to picomolar or nanomolar concentrations. One example
of this is MeuNaTxa-12 that is selective for DmNav (Para) channels
with an EC50 of 20 nM, but when applied at micromolar
D.M. Housley et al. / Neuropharmacology 127 (2017) 46e7874conentrations it modulates five more channels (Zhu et al., 2013). In
addition, toxins such as Charbydotoxin andMaurotoxinwere found
to be particularly promiscuous across ion channel subfamilies. As
such it is important within the literature to establish minimal
effective concentrations for SCTX peptides to avoid confounding
comparison of peptide selectivity. It was frequently difficult to
comment on SCTX selectivitiy as the vast majority of peptides have
only been screened against an extremely limited number of ion
channel subtypes. In addition publication bias towards positive
findings of peptide action may have limited the extent of channel
screening reported. This impedes understanding of toxin effects,
and can lead to false assumptions surrounding peptide specificity.
It is important to note the intrinsic variability of SCTX peptide
channel affinity and potency highlighted by this review. A sub-
stantial contributor to this is the variation in experimental pro-
tocols between groups, including the use of different channel
orthologues. One example is seen with the SCTX peptides ErgTx1,
CeERG4, and CeErg5, whichwere found to act on rat, but not human
ERG2 channel orthologues ,(Restano-Cassulini et al., 2006, 2008).
This underlies the importance of research groups providing this
critical information about their models, which is frequently not the
case. However even when essentially identical experimental pro-
tocols were reported, there was variation in SCTX peptide activity
on the same channels. For example, a recent publication replicating
the work of four previous calcin peptide experiments found that
while three calcins had similar action on RyR1 channels to what
had been previously described, hemicalcin only induced approxi-
mately half the predicted subconductance (Xiao et al., 2016). This
underlies the need for further replication within the field, and it is
important that readers interpret the reported absolute affinity/ef-
ficacy figures as a guide.
At a broader level, it was apparent that research has focused
primarily on the characterisation of SCTX peptide effects on sodium
and potassium channels, potentially at the expense of furthering
understanding of their actions on calcium and chloride channels.
For example this review has highlighted that only recently has a
SCTX peptide been determined to act on a CIC channel, and another
on a CFTR channel (Thompson et al., 2009;Fuller et al., 2007). The
further characterisation of these channel actions, and the identifi-
cation of specific modulators has tremendous pharmacological and
therapeutic potential.
The high specificity and affinity of scorpion toxin peptides has
led to their use as pharmacological tools to characterize ion channel
function in both normal physiology and in disease states (du Plessis
et al., 2008). SCTX peptides are also a focus for agrochemical lead
compounds for novel invertebrate-specific insecticides (Ortiz and
Possani, 2015). Continuing SCTX peptide research has great po-
tential for the development of novel pharmaceuticals capable of
specifically modulating channel function (Kuyucak and Norton,
2014). Such development has obvious implications towards the
treatment of a range of chronic medical conditions including
neurodegenerative and cardiovascular disease (Fuller et al., 2007).
Cancer therapy also benefits from SCTX research, where Chlor-
otoxin (Leiurus quinquestriatus), a small conductance chloride ion
channel inhibitor, has been modified for use as a targeted radio-
therapy agent and imaging peptide, and is currently under clinical
trial for use against a range of cancers (Dardevet et al., 2015;Stroud
et al., 2011). Similarly discovery and modification of SCTX peptides
and componds similar to Kurtoxin, that selectively target voltage-
gated calcium channels, protend significant advances in chronic
pain management (Swayne and Bourinet, 2008).
5. Conclusions
Scorpion toxins have a broad spectrum of action withinexcitable cells and have become a valuable source of highly specific
molecular tools for the study of ion channels. This field is advancing
as molecular techniques continue to make isolation of specific
peptides and expression of particular ion channel subclasses easier.
This review has catalogued the unique specificities of 320 indi-
vidual SCTX peptides that collectively act on 41 ion channel types.
Overall the SCTX peptides have evolved over millions of years of
selection to become highly selective and potent ion channel mod-
ulators. Some, such as calcins, are able to readily cross the plasma
membrane to activate Ca2þ stores, as well as acting as co-
transporters for other molecules. Research in this area is destined
to provide a rich dividend in molecular discovery that will expand
knowledge of ion channel function and facilitate the development
of significant clinical translational opportunities.
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